Eyepoint Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Eyepoint Pharmaceuticals Inc together

Penke I guess you are interested in Eyepoint Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eyepoint Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Eyepoint Pharmaceuticals Inc

I send you an email if I find something interesting about Eyepoint Pharmaceuticals Inc.

Quick analysis of Eyepoint Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

$5.34

Expected worth in 1 year

$8.76

How sure are you?

40.0%

+ What do you gain per year?

Total Gains per Share

$3.41

Return On Investment

19.5%

For what price can you sell your share?

Current Price per Share

$17.50

Expected price per share

$9.1 - $23.97

How sure are you?

50%

1. Valuation of Eyepoint Pharmaceuticals Inc (5 min.)

Live pricePrice per Share (EOD)

$17.50

Book Value per Share

$5.34

Intrinsic Value Per Share

$-33.74 - $-11.96

Total Value Per Share

$-28.40 - $-6.62

My calculation of the intrinsic value of Eyepoint Pharmaceuticals Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.13) 3Y: ($-0.20) TTM: ($-0.01)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($-0.01) 3Y: ($-0.05) TTM: ($0.00)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-1.24	$-0.63	$-1.59 - $-0.71
2	$-3.14	$-1.41	$-2.39 - $-0.89
3	$-5.61	$-2.33	$-3.18 - $-1.06
4	$-8.58	$-3.38	$-3.97 - $-1.23
5	$-12.00	$-4.55	$-4.77 - $-1.41
6	$-15.79	$-5.84	$-5.56 - $-1.58
7	$-19.90	$-7.23	$-6.36 - $-1.76
8	$-24.30	$-8.72	$-7.15 - $-1.93
9	$-28.92	$-10.30	$-7.95 - $-2.11
10	$-33.74	$-11.96	$-8.74 - $-2.28

2. Growth of Eyepoint Pharmaceuticals Inc (5 min.)

Is Eyepoint Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$266.3m	$137.7m	-$22.5m	-19.6%

How much money is Eyepoint Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$17.8m	-$31.1m	$13.3m	75.1%
Net Profit Margin	-179.0%	-301.3%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Eyepoint Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#192 / 1016

Most Revenue
#293 / 1016

Most Profit
#673 / 1016

Most Efficient
#624 / 1016

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc? (5 min.)

Welcome investor! Eyepoint Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Eyepoint Pharmaceuticals Inc.

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc?

First you should know what it really means to hold a share of Eyepoint Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Eyepoint Pharmaceuticals Inc is $17.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Eyepoint Pharmaceuticals Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eyepoint Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.34. Based on the TTM, the Book Value Change Per Share is $0.85 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.44 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Eyepoint Pharmaceuticals Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.28	-1.6%	-0.36	-2.0%	-0.51	-2.9%	-0.33	-1.9%	-0.24	-1.4%
Usd Book Value Change Per Share	4.17	23.8%	0.85	4.9%	-0.44	-2.5%	0.23	1.3%	0.13	0.7%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	4.17	23.8%	0.85	4.9%	-0.44	-2.5%	0.23	1.3%	0.13	0.7%
Usd Price Per Share	23.11	-	10.69	-	7.86	-	6.58	-	4.74	-
Price to Earnings Ratio	-20.42	-	-8.69	-	-4.66	-	-5.27	-	-13.65	-
Price-to-Total Gains Ratio	5.54	-	67.46	-	-22.62	-	6.59	-	5.26	-
Price to Book Ratio	4.32	-	5.14	-	2.73	-	5.22	-	6.49	-
Price-to-Total Gains Ratio	5.54	-	67.46	-	-22.62	-	6.59	-	5.26	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	17.5
Number of shares	57

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.85	0.23
Usd Total Gains Per Share	0.85	0.23
Gains per Quarter (57 shares)	48.60	13.08
Gains per Year (57 shares)	194.41	52.32

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	194	184	0	52	42
2	0	389	378	0	105	94
3	0	583	572	0	157	146
4	0	778	766	0	209	198
5	0	972	960	0	262	250
6	0	1166	1154	0	314	302
7	0	1361	1348	0	366	354
8	0	1555	1542	0	419	406
9	0	1750	1736	0	471	458
10	0	1944	1930	0	523	510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	4.0	0.0	0.0%	0.0	12.0	0.0	0.0%	0.0	20.0	0.0	0.0%	1.0	39.0	0.0	2.5%	2.0	72.0	0.0	2.7%
Book Value Change Per Share	2.0	2.0	0.0	50.0%	4.0	8.0	0.0	33.3%	8.0	12.0	0.0	40.0%	16.0	24.0	0.0	40.0%	28.0	46.0	0.0	37.8%
Dividend per Share	0.0	0.0	4.0	0.0%	0.0	0.0	12.0	0.0%	0.0	0.0	20.0	0.0%	0.0	0.0	40.0	0.0%	0.0	0.0	74.0	0.0%
Total Gains per Share	2.0	2.0	0.0	50.0%	4.0	8.0	0.0	33.3%	8.0	12.0	0.0	40.0%	16.0	24.0	0.0	40.0%	28.0	46.0	0.0	37.8%

Fundamentals of Eyepoint Pharmaceuticals Inc

About Eyepoint Pharmaceuticals Inc

https://eyepointpharma.com
Biotechnology
121
480 Pleasant Street, Watertown, MA, United States, 02472
Google Maps Bing Maps

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 07:29:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Eyepoint Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Eyepoint Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of -100.5% means that $-1.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eyepoint Pharmaceuticals Inc:

The MRQ is -100.5%. The company is making a huge loss. -2
The TTM is -179.0%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-100.5%	TTM	-179.0%	+78.5%
TTM	-179.0%	YOY	-301.3%	+122.3%
TTM	-179.0%	5Y	-257.2%	+78.1%
5Y	-257.2%	10Y	-879.0%	+621.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-100.5%	-197.2%	+96.7%
TTM	-179.0%	-210.4%	+31.4%
YOY	-301.3%	-279.3%	-22.0%
5Y	-257.2%	-436.8%	+179.6%
10Y	-879.0%	-599.3%	-279.7%

Measures how much net profit Eyepoint Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Eyepoint Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Eyepoint Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Eyepoint Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Eyepoint Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Eyepoint Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Eyepoint Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Eyepoint Pharmaceuticals Inc is -1.01. This means that Eyepoint Pharmaceuticals Inc earned $-1.01 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -197.2%.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Eyepoint Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Eyepoint Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Eyepoint Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Eyepoint Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Eyepoint Pharmaceuticals Inc = -14,099
Total revenue MRQ Eyepoint Pharmaceuticals Inc = 14,028
$-14,099 / $14,028 = -1.01 or -100.5%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Eyepoint Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
-4.0% Return on Assets means that Eyepoint Pharmaceuticals Inc generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eyepoint Pharmaceuticals Inc:

The MRQ is -4.0%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -9.7%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-4.0%	TTM	-9.7%	+5.7%
TTM	-9.7%	YOY	-15.4%	+5.7%
TTM	-9.7%	5Y	-12.8%	+3.1%
5Y	-12.8%	10Y	-16.0%	+3.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-4.0%	-13.6%	+9.6%
TTM	-9.7%	-12.9%	+3.2%
YOY	-15.4%	-11.9%	-3.5%
5Y	-12.8%	-14.2%	+1.4%
10Y	-16.0%	-16.2%	+0.2%

Shows how efficient Eyepoint Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Eyepoint Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (-4.0%) from Eyepoint Pharmaceuticals Inc are higher than the Biotechnology mean (-13.6%) that means Eyepoint Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Eyepoint Pharmaceuticals Inc is -4.0%. This means the company generated $-0.04 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.6%.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Eyepoint Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Eyepoint Pharmaceuticals Inc = -14,099
Total assets MRQ (balance sheet) from Eyepoint Pharmaceuticals Inc = 355,184
-14,099 / 355,184 = -0.04 or -4.0%

ROA is an important ratio as it will tell you how effectively Eyepoint Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Eyepoint Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
-5.3% Return on Equity means Eyepoint Pharmaceuticals Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eyepoint Pharmaceuticals Inc:

The MRQ is -5.3%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -23.6%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-5.3%	TTM	-23.6%	+18.3%
TTM	-23.6%	YOY	-26.6%	+3.0%
TTM	-23.6%	5Y	-56.6%	+33.0%
5Y	-56.6%	10Y	-50.5%	-6.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-5.3%	-17.0%	+11.7%
TTM	-23.6%	-16.1%	-7.5%
YOY	-26.6%	-15.4%	-11.2%
5Y	-56.6%	-20.0%	-36.6%
10Y	-50.5%	-21.1%	-29.4%

Shows how efficient Eyepoint Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Eyepoint Pharmaceuticals Inc is -5.3%. This means Eyepoint Pharmaceuticals Inc generated $-0.05 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -17.0%.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if Eyepoint Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Eyepoint Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Eyepoint Pharmaceuticals Inc = -14,099
Shareholders equity (balance sheet) MRQ Eyepoint Pharmaceuticals Inc = 266,323
-14,099 / 266,323 = -0.05 or -5.3%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Eyepoint Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Eyepoint Pharmaceuticals Inc is operating .

Measures how much profit Eyepoint Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of -116.6% means the company generated $-1.17 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eyepoint Pharmaceuticals Inc:

The MRQ is -116.6%. The company is operating very inefficient. -2
The TTM is -185.5%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-116.6%	TTM	-185.5%	+68.9%
TTM	-185.5%	YOY	-191.3%	+5.9%
TTM	-185.5%	5Y	-211.0%	+25.6%
5Y	-211.0%	10Y	-673.9%	+462.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-116.6%	-286.1%	+169.5%
TTM	-185.5%	-224.4%	+38.9%
YOY	-191.3%	-288.4%	+97.1%
5Y	-211.0%	-475.2%	+264.2%
10Y	-673.9%	-624.7%	-49.2%

Measures how efficient Eyepoint Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Eyepoint Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Eyepoint Pharmaceuticals Inc is -116.6%. This means that Eyepoint Pharmaceuticals Inc earned $-1.17 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -286.1%.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Eyepoint Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Eyepoint Pharmaceuticals Inc = -16,354
Total revenue MRQ Eyepoint Pharmaceuticals Inc = 14,028
$-16,354 / $14,028 = -1.17 or -116.6%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Eyepoint Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 2.17 means that the operating costs are $2.17 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eyepoint Pharmaceuticals Inc:

The MRQ is 2.166. The company is inefficient in keeping operating costs low. -1
The TTM is 2.855. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	2.166	TTM	2.855	-0.689
TTM	2.855	YOY	2.913	-0.059
TTM	2.855	5Y	3.126	-0.271
5Y	3.126	10Y	12.381	-9.255

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.166	2.997	-0.831
TTM	2.855	3.247	-0.392
YOY	2.913	3.766	-0.853
5Y	3.126	5.675	-2.549
10Y	12.381	7.857	+4.524

Measures how efficient Eyepoint Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Eyepoint Pharmaceuticals Inc is 216.6%. This means that Eyepoint Pharmaceuticals Inc earned $2.17 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.00.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(998 +29,384) \ 14,028 = 2.17

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Eyepoint Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Eyepoint Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 5.45 means the company has $5.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eyepoint Pharmaceuticals Inc:

The MRQ is 5.450. The company is very able to pay all its short-term debts. +2
The TTM is 3.897. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	5.450	TTM	3.897	+1.554
TTM	3.897	YOY	5.912	-2.015
TTM	3.897	5Y	5.500	-1.603
5Y	5.500	10Y	6.107	-0.607

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.450	3.930	+1.520
TTM	3.897	4.251	-0.354
YOY	5.912	5.436	+0.476
5Y	5.500	6.045	-0.545
10Y	6.107	6.363	-0.256

Measures if Eyepoint Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Eyepoint Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Eyepoint Pharmaceuticals Inc is 5.45. This means Eyepoint Pharmaceuticals Inc has $5.45 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.93.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
344,800 \ 63,263) = 5.45

The current ratio measures if Eyepoint Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Eyepoint Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Eyepoint Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Eyepoint Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Eyepoint Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 6.03 means the company can pay off $6.03 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eyepoint Pharmaceuticals Inc:

The MRQ is 6.033. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 3.994. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	6.033	TTM	3.994	+2.038
TTM	3.994	YOY	7.871	-3.876
TTM	3.994	5Y	5.631	-1.636
5Y	5.631	10Y	6.769	-1.138

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	6.033	3.629	+2.404
TTM	3.994	4.065	-0.071
YOY	7.871	5.397	+2.474
5Y	5.631	5.993	-0.362
10Y	6.769	6.277	+0.492

Measures if Eyepoint Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Eyepoint Pharmaceuticals Inc can pay off its short term debts. This shows if Eyepoint Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Eyepoint Pharmaceuticals Inc is 6.03. This means that Eyepoint Pharmaceuticals Inc can pay off $6.03 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.63.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Eyepoint Pharmaceuticals Inc: (331,050 + 49,787 +805) / 63,263 = 6.03

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Eyepoint Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Eyepoint Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Eyepoint Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.25 means that Eyepoint Pharmaceuticals Inc assets are financed with 25.0% credit (debt) and the remaining percentage (100% - 25.0%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Eyepoint Pharmaceuticals Inc:

The MRQ is 0.250. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.513. The company is able to pay all its debts by selling its assets. +1

Trends

Current period		Compared to		+/-
MRQ	0.250	TTM	0.513	-0.263
TTM	0.513	YOY	0.379	+0.134
TTM	0.513	5Y	0.583	-0.071
5Y	0.583	10Y	0.476	+0.108

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.250	0.332	-0.082
TTM	0.513	0.334	+0.179
YOY	0.379	0.268	+0.111
5Y	0.583	0.366	+0.217
10Y	0.476	0.390	+0.086

Measures how much % of Eyepoint Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Eyepoint Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Eyepoint Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Eyepoint Pharmaceuticals Inc is 0.25. This means means that Eyepoint Pharmaceuticals Inc is financed with 25.0% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 393.0%.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Eyepoint Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
88,861 \ 355,184 = 25.0% or 0.25.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Eyepoint Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 33.4% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eyepoint Pharmaceuticals Inc:

The MRQ is 0.334. The company is very able to pay all its debts with equity. +2
The TTM is 1.276. The company is able to pay all its debts with equity. +1

Trends

Current period		Compared to		+/-
MRQ	0.334	TTM	1.276	-0.942
TTM	1.276	YOY	0.624	+0.652
TTM	1.276	5Y	2.991	-1.715
5Y	2.991	10Y	1.971	+1.020

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.334	0.381	-0.047
TTM	1.276	0.390	+0.886
YOY	0.624	0.334	+0.290
5Y	2.991	0.434	+2.557
10Y	1.971	0.466	+1.505

Measures if Eyepoint Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Eyepoint Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Eyepoint Pharmaceuticals Inc is 0.33. This means that Eyepoint Pharmaceuticals Inc can pay off $0.33 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.38.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
88,861 \ 266,323 = 0.33 or 33.4%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Eyepoint Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eyepoint Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of -20.42 means the investor is paying $-20.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eyepoint Pharmaceuticals Inc:

The EOD is -15.463. Based on the earnings, the company is expensive. -2
The MRQ is -20.420. Based on the earnings, the company is expensive. -2
The TTM is -8.693. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-15.463	MRQ	-20.420	+4.957
MRQ	-20.420	TTM	-8.693	-11.727
TTM	-8.693	YOY	-4.655	-4.038
TTM	-8.693	5Y	-5.272	-3.421
5Y	-5.272	10Y	-13.655	+8.383

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-15.463	-2.315	-13.148
MRQ	-20.420	-2.560	-17.860
TTM	-8.693	-2.664	-6.029
YOY	-4.655	-4.122	-0.533
5Y	-5.272	-6.258	+0.986
10Y	-13.655	-6.108	-7.547

Measures how much money you pay for each share for every $1 in earnings Eyepoint Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Eyepoint Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Eyepoint Pharmaceuticals Inc is -20.42. This means the investor is paying $-20.42 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.56.
What is the trend?
The trend is important because it shows you how Eyepoint Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Eyepoint Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Eyepoint Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Eyepoint Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 42,168 = EPS
PE ratio MRQ = -20.42

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eyepoint Pharmaceuticals Inc:

The EOD is -9.087. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -12.000. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -4.520. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-9.087	MRQ	-12.000	+2.913
MRQ	-12.000	TTM	-4.520	-7.479
TTM	-4.520	YOY	-5.677	+1.156
TTM	-4.520	5Y	-3.660	-0.861
5Y	-3.660	10Y	-5.988	+2.329

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-9.087	-3.067	-6.020
MRQ	-12.000	-3.251	-8.749
TTM	-4.520	-3.545	-0.975
YOY	-5.677	-5.595	-0.082
5Y	-3.660	-8.315	+4.655
10Y	-5.988	-8.708	+2.720

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Eyepoint Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 4.32 means the investor is paying $4.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eyepoint Pharmaceuticals Inc:

The EOD is 3.274. Based on the equity, the company is fair priced.
The MRQ is 4.324. Based on the equity, the company is fair priced.
The TTM is 5.139. Based on the equity, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	3.274	MRQ	4.324	-1.050
MRQ	4.324	TTM	5.139	-0.815
TTM	5.139	YOY	2.730	+2.409
TTM	5.139	5Y	5.222	-0.083
5Y	5.222	10Y	6.494	-1.272

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	3.274	1.905	+1.369
MRQ	4.324	2.111	+2.213
TTM	5.139	2.095	+3.044
YOY	2.730	2.836	-0.106
5Y	5.222	3.443	+1.779
10Y	6.494	3.794	+2.700

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eyepoint Pharmaceuticals Inc.

3.1. Institutions holding Eyepoint Pharmaceuticals Inc

Institutions are holding 104.034% of the shares of Eyepoint Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Cormorant Asset Management, LLC	12.1175	6.6644	6038235	2838235	88.6948
2023-12-31	Franklin Resources Inc	9.3128	0.0502	4640651	488206	11.7571
2023-12-31	Adage Capital Partners Gp LLC	8.9632	0.2137	4466420	2729917	157.2077
2023-12-31	Suvretta Capital Management, LLC	8.1412	4.2387	4056847	564700	16.1706
2023-12-31	T. Rowe Price Associates, Inc.	5.0625	0.0078	2522704	1148358	83.5567
2023-12-31	Essex Woodlands Health Ventures	4.6914	13.3697	2337786	-1153135	-33.0324
2023-12-31	BlackRock Inc	4.3533	0.0013	2169306	339856	18.5769
2023-12-31	Vanguard Group Inc	4.0819	0.001	2034060	593336	41.1832
2023-12-31	T. Rowe Price Investment Management,Inc.	3.1279	0.0234	1558675	1558675	0
2023-12-31	Ameriprise Financial Inc	3.0827	0.0106	1536125	1525776	14743.2216
2023-12-31	Morgan Stanley - Brokerage Accounts	2.6468	0.0027	1318897	1182076	863.958
2023-12-31	Goldman Sachs Group Inc	2.2797	0.0024	1135972	535498	89.1792
2023-12-31	Millennium Management LLC	2.2649	0.0113	1128638	548009	94.382
2023-12-31	Jennison Associates LLC	2.1397	0.0184	1066240	1066240	0
2023-09-30	Citadel Advisors Llc	2.1253	0.0018	1059047	211284	24.9225
2023-12-31	Deutsche Bank AG	1.5462	0.0091	770503	748739	3440.2637
2023-12-31	Geode Capital Management, LLC	1.3695	0.0017	682417	146842	27.4176
2023-12-31	Federated Hermes Inc	1.3542	0.0387	674824	445289	193.9961
2023-12-31	Perceptive Advisors LLC	1.1833	0.3042	589646	589646	0
2023-12-31	UBS Group AG	1.1522	0.004	574169	47321	8.9819
Total		80.9962	24.9751	40361162	+16154868	+40.0%

3.2. Funds holding Eyepoint Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Franklin US Small Cap Growth Equity	3.2733	1.3597	1631100	160100	10.8838
2024-02-29	Franklin Biotechnology Discv A(acc)USD	2.8387	2.0855	1414563	-340778	-19.4138
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.5159	0.0022	1253709	0	0
2023-12-31	US Small-Cap Growth II Equity Comp	2.4637	0.1143	1227671	553332	82.0555
2023-12-31	T. Rowe Price New Horizons	2.4637	0.1147	1227671	553332	82.0555
2024-02-29	Franklin Small Cap Growth Adv	2.3935	1.1191	1192700	-384100	-24.3595
2024-03-28	iShares Russell 2000 ETF	1.8243	0.0287	909050	438	0.0482
2024-02-29	Franklin Biotechnology Discovery A	1.4876	2.0971	741283	-134850	-15.3915
2024-02-29	PGIM Jennison Health Sciences Z	1.1624	0.8776	579249	-69906	-10.7688
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.0607	0.0141	528571	-480	-0.0907
2024-02-29	Columbia Small Cap Growth Inst	0.887	0.6236	441993	-79305	-15.213
2023-12-31	T. Rowe Price Small-Cap Value	0.8294	0.0903	413311	413311	0
2023-12-31	Federated Hermes MDT SCC Institutional	0.7508	0.7307	374125	326519	685.8778
2023-12-31	Federated Hermes MDT Small Cap Core IS	0.7508	0.7326	374125	326519	685.8778
2023-12-31	T. Rowe Price US Small-Cap Core Equity	0.7384	0.0896	367972	367972	0
2023-12-31	T. Rowe Price Small-Cap Stock	0.7384	0.0899	367972	367972	0
2024-02-29	Candriam Eqs L Biotech C USD Cap	0.6321	0.5215	315000	75000	31.25
2023-12-31	Federated Hermes MDT Small Cap Growth IS	0.5523	1.3657	275198	100214	57.2704
2023-12-31	Federated Hermes MDT SCG Institutional	0.5523	1.3609	275198	100214	57.2704
2024-01-31	Fidelity Small Cap Index	0.5428	0.0294	270478	4516	1.698
Total		28.4581	13.4472	14180939	+2340020	+16.5%

3.3. Insider Transactions

Insiders are holding 1.022% of the shares of Eyepoint Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price
2024-02-02	David Scott Jones	SELL	209	28.49
2024-01-26	Dario A Paggiarino	SELL	49325	25.66
2024-01-25	David Scott Jones	SELL	600	25
2024-01-23	Dario A Paggiarino	SELL	5135	25
2024-01-23	David Scott Jones	SELL	900	25
2024-01-11	Cormorant Asset Management, Lp	BUY	750000	19.75
2024-01-11	Ye Liu	SELL	1910500	19.45
2024-01-09	Cormorant Asset Management, Lp	BUY	105000	21.32
2024-01-08	Dario A Paggiarino	SELL	22913	21.13
2023-12-13	Dario A Paggiarino	SELL	1458	20
2023-12-08	Cormorant Asset Management, Lp	BUY	588235	17
2023-12-06	Ye Liu	SELL	266242	18.41
2023-12-04	Cormorant Asset Management, Lp	BUY	1919057	21.82
2023-12-04	Michael Craig Pine	SELL	45000	22
2023-09-01	Ew Healthcare Partners, L.p.	SELL	20000	9.9
2023-08-30	Ew Healthcare Partners, L.p.	SELL	60976	10.92
2023-08-28	Ew Healthcare Partners, L.p.	SELL	60858	11.71
2023-08-24	Ew Healthcare Partners, L.p.	SELL	139280	14.62
2023-08-22	Ew Healthcare Partners, L.p.	SELL	46778	14.62
2023-05-30	Ye Liu	SELL	1	6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Eyepoint Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	4.168	0.853	+389%	-0.442	+111%	0.229	+1716%	0.127	+3174%
Book Value Per Share	-	-	5.345	2.311	+131%	2.764	+93%	1.636	+227%	1.025	+421%
Current Ratio	-	-	5.450	3.897	+40%	5.912	-8%	5.500	-1%	6.107	-11%
Debt To Asset Ratio	-	-	0.250	0.513	-51%	0.379	-34%	0.583	-57%	0.476	-47%
Debt To Equity Ratio	-	-	0.334	1.276	-74%	0.624	-47%	2.991	-89%	1.971	-83%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.283	-0.355	+26%	-0.513	+81%	-0.335	+18%	-0.236	-16%
Free Cash Flow Per Share	-	-	-0.481	-0.008	-98%	-0.337	-30%	-0.191	-60%	-0.134	-72%
Free Cash Flow To Equity Per Share	-	-	3.903	0.930	+319%	-0.340	+109%	0.285	+1270%	0.166	+2251%
Gross Profit Margin	-	-	1.013	1.137	-11%	1.267	-20%	1.433	-29%	1.230	-18%
Intrinsic Value_10Y_max	-	-	-11.964	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-33.742	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.633	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-1.243	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-2.333	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-5.609	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-4.554	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-11.995	-	-	-	-	-	-	-	-
Market Cap	872039000.000	-32%	1151589788.000	532442098.000	+116%	391545511.000	+194%	327999032.454	+251%	236079768.427	+388%
Net Profit Margin	-	-	-1.005	-1.790	+78%	-3.013	+200%	-2.572	+156%	-8.790	+775%
Operating Margin	-	-	-1.166	-1.855	+59%	-1.913	+64%	-2.110	+81%	-6.739	+478%
Operating Ratio	-	-	2.166	2.855	-24%	2.913	-26%	3.126	-31%	12.381	-83%
Pb Ratio	3.274	-32%	4.324	5.139	-16%	2.730	+58%	5.222	-17%	6.494	-33%
Pe Ratio	-15.463	+24%	-20.420	-8.693	-57%	-4.655	-77%	-5.272	-74%	-13.655	-33%
Price Per Share	17.500	-32%	23.110	10.685	+116%	7.858	+194%	6.582	+251%	4.738	+388%
Price To Free Cash Flow Ratio	-9.087	+24%	-12.000	-4.520	-62%	-5.677	-53%	-3.660	-70%	-5.988	-50%
Price To Total Gains Ratio	4.199	-32%	5.544	67.462	-92%	-22.617	+508%	6.589	-16%	5.258	+5%
Quick Ratio	-	-	6.033	3.994	+51%	7.871	-23%	5.631	+7%	6.769	-11%
Return On Assets	-	-	-0.040	-0.097	+145%	-0.154	+288%	-0.128	+223%	-0.160	+303%
Return On Equity	-	-	-0.053	-0.236	+346%	-0.266	+403%	-0.566	+970%	-0.505	+854%
Total Gains Per Share	-	-	4.168	0.853	+389%	-0.442	+111%	0.229	+1716%	0.127	+3174%
Usd Book Value	-	-	266323000.000	115149000.000	+131%	137725750.000	+93%	81517550.000	+227%	51069475.000	+421%
Usd Book Value Change Per Share	-	-	4.168	0.853	+389%	-0.442	+111%	0.229	+1716%	0.127	+3174%
Usd Book Value Per Share	-	-	5.345	2.311	+131%	2.764	+93%	1.636	+227%	1.025	+421%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.283	-0.355	+26%	-0.513	+81%	-0.335	+18%	-0.236	-16%
Usd Free Cash Flow	-	-	-23992000.000	-402000.000	-98%	-16788750.000	-30%	-9536250.000	-60%	-6681300.000	-72%
Usd Free Cash Flow Per Share	-	-	-0.481	-0.008	-98%	-0.337	-30%	-0.191	-60%	-0.134	-72%
Usd Free Cash Flow To Equity Per Share	-	-	3.903	0.930	+319%	-0.340	+109%	0.285	+1270%	0.166	+2251%
Usd Market Cap	872039000.000	-32%	1151589788.000	532442098.000	+116%	391545511.000	+194%	327999032.454	+251%	236079768.427	+388%
Usd Price Per Share	17.500	-32%	23.110	10.685	+116%	7.858	+194%	6.582	+251%	4.738	+388%
Usd Profit	-	-	-14099000.000	-17804250.000	+26%	-31181000.000	+121%	-17827250.000	+26%	-12356875.000	-12%
Usd Revenue	-	-	14028000.000	11504500.000	+22%	10351000.000	+36%	8958100.000	+57%	5576475.000	+152%
Usd Total Gains Per Share	-	-	4.168	0.853	+389%	-0.442	+111%	0.229	+1716%	0.127	+3174%
	EOD	+2 -6	MRQ	TTM	+28 -6	YOY	+26 -8	5Y	+27 -7	10Y	+24 -10

4.2. Fundamental Score

Let's check the fundamental score of Eyepoint Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-15.463
Price to Book Ratio (EOD)	Between	0-1	3.274
Net Profit Margin (MRQ)	Greater than	0	-1.005
Operating Margin (MRQ)	Greater than	0	-1.166
Quick Ratio (MRQ)	Greater than	1	6.033
Current Ratio (MRQ)	Greater than	1	5.450
Debt to Asset Ratio (MRQ)	Less than	1	0.250
Debt to Equity Ratio (MRQ)	Less than	1	0.334
Return on Equity (MRQ)	Greater than	0.15	-0.053
Return on Assets (MRQ)	Greater than	0.05	-0.040
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Eyepoint Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	30.099
Ma 20	Greater than	Ma 50	21.104
Ma 50	Greater than	Ma 100	24.096
Ma 100	Greater than	Ma 200	22.315
Open	Greater than	Close	20.790
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	355,184
Total Liabilities	88,861
Total Stockholder Equity	266,323

	As reported
Total Liabilities	88,861
Total Stockholder Equity	+ 266,323
Total Assets	= 355,184

Assets

Total Assets	355,184
Total Current Assets	344,800
Long-term Assets	10,384

Total Current Assets

Total Current Assets (as reported)	344,800
Cash And Cash Equivalents	281,263
Short-term Investments	49,787
Net Receivables	805
Inventory	3,906
Other Current Assets	9,039
Total Current Assets (calculated)	344,800
+/-	0

Long-term Assets

Long-term Assets (as reported)	10,384
Property Plant Equipment	10,234
Long-term Assets Other	150
Long-term Assets (calculated)	10,384
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	63,263
Long-term Liabilities	25,598
Total Stockholder Equity	266,323

Total Current Liabilities

Total Current Liabilities (as reported)	63,263
Short-term Debt	563
Accounts payable	6,504
Other Current Liabilities	17,604
Total Current Liabilities (calculated)	24,671
+/-	38,592

Long-term Liabilities

Long-term Liabilities (as reported)	25,598
Capital Lease Obligations	4,906
Long-term Liabilities (calculated)	4,906
+/-	20,692

Total Stockholder Equity

Total Stockholder Equity (as reported)	266,323
Common Stock	49
Retained Earnings	-742,146
Accumulated Other Comprehensive Income	864
Other Stockholders Equity	1,007,556
Total Stockholder Equity (calculated)	266,323
+/-	0

Other

Capital Stock	49
Cash and Short Term Investments	331,050
Common Stock Shares Outstanding	42,168
Current Deferred Revenue	38,592
Liabilities and Stockholders Equity	355,184
Net Debt	-275,794
Net Invested Capital	266,323
Net Working Capital	281,537
Property Plant and Equipment Gross	12,805
Short Long Term Debt Total	5,469

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

> Total Assets

0
0
0
4,820
0
0
0
28,051
0
70,147
0
62,298
0
186,698
0
174,848
0
97,600
0
86,118
116,327
107,670
115,866
55,784
47,161
39,231
36,371
37,104
34,492
32,630
29,918
43,014
41,000
38,688
46,940
47,113
43,140
24,948
22,833
20,597
23,339
21,042
19,120
16,249
22,735
20,819
26,021
22,671
43,740
40,180
35,702
32,367
27,460
23,950
36,165
31,619
24,933
19,746
17,505
18,677
13,327
14,197
50,158
71,670
88,855
78,168
81,854
91,330
79,067
73,323
80,290
69,685
76,791
91,717
187,140
178,823
168,251
263,372
244,555
233,433
220,490
180,356
154,593
175,655
160,043
355,184

355,184

160,043

175,655

154,593

180,356

220,490

233,433

244,555

263,372

168,251

178,823

187,140

91,717

76,791

69,685

80,290

73,323

79,067

91,330

81,854

78,168

88,855

71,670

50,158

14,197

13,327

18,677

17,505

19,746

24,933

31,619

36,165

23,950

27,460

32,367

35,702

40,180

43,740

22,671

26,021

20,819

22,735

16,249

19,120

21,042

23,339

20,597

22,833

24,948

43,140

47,113

46,940

38,688

41,000

43,014

29,918

32,630

34,492

37,104

36,371

39,231

47,161

55,784

115,866

107,670

116,327

86,118

97,600

174,848

186,698

62,298

70,147

28,051

4,820

> Total Current Assets

0
0
0
880
0
0
0
22,049
0
0
0
10,574
0
0
0
12,682
0
6,164
0
5,688
19,353
13,145
22,406
17,690
13,181
10,906
9,367
8,127
7,096
6,060
5,132
19,034
17,052
15,858
24,338
25,366
22,280
19,853
17,895
15,959
18,900
16,810
15,205
12,464
19,112
17,232
22,462
19,342
40,685
37,348
33,077
29,838
25,163
21,862
34,278
29,963
23,503
18,535
16,470
17,740
12,547
13,645
17,675
39,909
57,642
47,601
48,372
58,573
47,061
42,069
49,694
39,832
47,592
63,118
159,353
151,826
141,775
237,745
219,629
205,866
192,102
172,808
146,057
167,118
150,163
344,800

344,800

150,163

167,118

146,057

172,808

192,102

205,866

219,629

237,745

141,775

151,826

159,353

63,118

47,592

39,832

49,694

42,069

47,061

58,573

48,372

47,601

57,642

39,909

17,675

13,645

12,547

17,740

16,470

18,535

23,503

29,963

34,278

21,862

25,163

29,838

33,077

37,348

40,685

19,342

22,462

17,232

19,112

12,464

15,205

16,810

18,900

15,959

17,895

19,853

22,280

25,366

24,338

15,858

17,052

19,034

5,132

6,060

7,096

8,127

9,367

10,906

13,181

17,690

22,406

13,145

19,353

5,688

6,164

12,682

10,574

22,049

880

Cash And Cash Equivalents

0
0
0
793
0
0
0
21,786
0
0
0
9,790
0
0
0
11,469
0
4,249
0
2,668
16,454
9,783
18,175
15,609
10,982
9,849
8,019
6,899
5,963
5,129
3,971
15,514
10,126
7,377
13,296
12,912
9,811
8,408
6,375
4,625
17,646
9,409
7,998
6,899
14,546
15,219
18,555
15,334
11,384
29,751
23,007
19,121
14,088
11,210
24,867
15,313
14,308
11,685
12,871
16,898
11,833
12,876
16,346
38,776
55,764
45,261
43,379
44,161
31,760
22,214
26,299
22,814
28,726
44,909
138,579
127,630
119,710
178,593
101,545
82,134
75,362
95,633
105,765
139,597
133,035
281,263

281,263

133,035

139,597

105,765

95,633

75,362

82,134

101,545

178,593

119,710

127,630

138,579

44,909

28,726

22,814

26,299

22,214

31,760

44,161

43,379

45,261

55,764

38,776

16,346

12,876

11,833

16,898

12,871

11,685

14,308

15,313

24,867

11,210

14,088

19,121

23,007

29,751

11,384

15,334

18,555

15,219

14,546

6,899

7,998

9,409

17,646

4,625

6,375

8,408

9,811

12,912

13,296

7,377

10,126

15,514

3,971

5,129

5,963

6,899

8,019

9,849

10,982

15,609

18,175

9,783

16,454

2,668

4,249

11,469

9,790

21,786

793

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,051
5,193
7,266
9,770
11,216
11,460
10,272
10,087
9,946
9,258
6,311
5,699
3,374
1,908
502
2,712
2,944
2,924
5,935
8,651
9,414
9,917
9,881
8,407
13,679
8,238
5,847
2,499
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,965
89,239
89,033
81,897
48,928
16,718
2,938
2,977
49,787

49,787

2,977

2,938

16,718

48,928

81,897

89,033

89,239

32,965

2,499

5,847

8,238

13,679

8,407

9,881

9,917

9,414

8,651

5,935

2,924

2,944

2,712

502

1,908

3,374

5,699

6,311

9,258

9,946

10,087

10,272

11,460

11,216

9,770

7,266

5,193

2,051

Net Receivables

0
0
0
69
0
0
0
237
0
0
0
539
0
0
0
744
0
1,621
0
2,508
2,899
3,362
4,231
1,467
1,829
885
879
815
833
788
713
1,111
1,487
1,094
832
843
723
1,016
985
967
938
948
1,035
597
1,112
636
613
517
25,462
727
430
622
569
573
472
488
462
457
300
251
287
288
478
353
489
288
2,258
9,598
8,855
11,720
14,390
7,350
9,392
9,453
12,332
15,111
13,602
18,354
19,589
22,594
20,876
15,503
10,422
10,952
483
805

805

483

10,952

10,422

15,503

20,876

22,594

19,589

18,354

13,602

15,111

12,332

9,453

9,392

7,350

14,390

11,720

8,855

9,598

2,258

288

489

353

478

288

287

251

300

457

462

488

472

573

569

622

430

727

25,462

517

613

636

1,112

597

1,035

948

938

967

985

1,016

723

843

832

1,094

1,487

1,111

713

788

833

815

879

885

1,829

1,467

4,231

3,362

2,899

2,508

1,621

744

539

237

Other Current Assets

0
0
0
18
0
0
0
27
0
73
0
245
0
378
0
0
0
294
0
-1
2,899
3,362
4,231
614
370
172
469
413
1,133
931
1,161
358
246
7,387
440
395
286
157
448
421
1,254
1,090
473
2,191
2,658
1,511
582
547
915
1,662
989
1,303
589
771
532
971
957
1,003
1,100
842
427
769
851
1,133
1,878
2,340
2,735
3,144
3,887
8,135
5,647
5,895
5,832
3,419
2,856
3,704
3,892
4,217
5,920
8,851
10,436
9,858
9,081
9,370
9,091
9,039

9,039

9,091

9,370

9,081

9,858

10,436

8,851

5,920

4,217

3,892

3,704

2,856

3,419

5,832

5,895

5,647

8,135

3,887

3,144

2,735

2,340

1,878

1,133

851

769

427

842

1,100

1,003

957

971

532

771

589

1,303

989

1,662

915

547

582

1,511

2,658

2,191

473

1,090

1,254

421

448

157

286

395

440

7,387

246

358

1,161

931

1,133

413

469

172

370

614

4,231

3,362

2,899

-1

294

378

245

> Long-term Assets

0
0
0
3,941
0
0
0
6,002
0
0
0
51,723
0
0
0
162,166
0
91,436
0
80,430
96,974
94,525
93,460
38,094
33,980
28,325
27,004
28,977
27,396
26,570
24,786
23,980
23,948
22,830
22,602
21,747
20,860
5,095
4,938
4,638
4,439
4,232
3,915
3,785
3,623
3,587
3,559
3,329
3,055
2,832
2,625
2,529
2,297
2,088
1,887
1,656
1,430
1,211
1,035
937
780
552
32,483
31,761
31,213
30,567
33,482
32,757
32,006
31,254
30,596
29,853
29,199
28,599
27,787
26,997
26,476
25,627
24,926
27,567
28,388
7,548
8,536
8,537
9,880
10,384

10,384

9,880

8,537

8,536

7,548

28,388

27,567

24,926

25,627

26,476

26,997

27,787

28,599

29,199

29,853

30,596

31,254

32,006

32,757

33,482

30,567

31,213

31,761

32,483

552

780

937

1,035

1,211

1,430

1,656

1,887

2,088

2,297

2,529

2,625

2,832

3,055

3,329

3,559

3,587

3,623

3,785

3,915

4,232

4,439

4,638

4,938

5,095

20,860

21,747

22,602

22,830

23,948

23,980

24,786

26,570

27,396

28,977

27,004

28,325

33,980

38,094

93,460

94,525

96,974

80,430

91,436

162,166

51,723

6,002

3,941

Property Plant Equipment

0
0
0
272
0
0
0
465
0
1,371
0
2,486
0
2,830
0
2,331
0
1,393
0
511
467
346
308
473
414
366
75
66
55
47
52
43
50
88
135
123
397
423
410
335
289
277
223
179
146
133
292
297
261
265
280
338
318
311
311
290
257
231
241
313
337
293
250
253
320
288
3,393
3,708
3,572
3,078
2,967
3,264
2,733
3,240
3,043
2,868
2,402
2,252
2,642
4,787
6,319
6,038
5,777
5,514
5,250
10,234

10,234

5,250

5,514

5,777

6,038

6,319

4,787

2,642

2,252

2,402

2,868

3,043

3,240

2,733

3,264

2,967

3,078

3,572

3,708

3,393

288

320

253

250

293

337

313

241

231

257

290

311

318

338

280

265

261

297

292

133

146

179

223

277

289

335

410

423

397

123

135

366

414

473

308

346

467

511

1,393

2,331

2,830

2,486

1,371

465

272

Goodwill

0
0
0
0
0
0
0
0
0
0
0
973,923
0
39,119
0
39,471
0
40,142
0
40,498
56,042
55,413
55,386
56,042
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

56,042

55,386

55,413

56,042

40,498

40,142

39,471

39,119

973,923

Intangible Assets

0
0
0
3,626
0
0
0
5,514
0
51,328
0
49,237
0
162,255
0
120,365
0
49,900
0
39,420
40,465
38,766
37,766
36,802
33,507
27,899
26,796
28,802
27,257
26,438
24,674
23,877
23,838
22,681
22,406
21,564
20,387
4,596
4,451
4,226
4,078
3,883
3,619
3,430
3,300
3,127
2,940
2,765
2,528
2,301
2,080
1,925
1,713
1,512
1,311
1,102
910
718
540
364
184
0
31,973
31,358
30,743
30,129
29,514
28,899
28,284
27,669
27,054
26,439
25,824
25,209
24,594
23,979
23,364
22,749
22,134
21,519
20,904
0
0
0
0
0

20,904

21,519

22,134

22,749

23,364

23,979

24,594

25,209

25,824

26,439

27,054

27,669

28,284

28,899

29,514

30,129

30,743

31,358

31,973

184

364

540

718

910

1,102

1,311

1,512

1,713

1,925

2,080

2,301

2,528

2,765

2,940

3,127

3,300

3,430

3,619

3,883

4,078

4,226

4,451

4,596

20,387

21,564

22,406

22,681

23,838

23,877

24,674

26,438

27,257

28,802

26,796

27,899

33,507

36,802

37,766

38,766

40,465

39,420

49,900

120,365

162,255

49,237

51,328

5,514

3,626

Other Assets

0
0
0
3,667
0
0
0
5,538
0
51,340
0
49,393
0
162,255
0
159,792
0
89,883
0
80,022
101,223
98,895
97,868
37,621
33,566
27,959
26,929
28,911
27,341
26,523
24,734
23,937
23,898
22,742
22,467
21,624
20,463
4,672
4,528
4,303
4,150
3,955
3,692
3,606
3,477
3,454
3,267
3,032
2,794
2,567
2,345
2,191
1,979
1,777
1,576
1,366
1,173
980
794
624
443
259
260
150
150
438
150
150
150
150
150
150
150
150
150
150
710
626
150
1,261
1,165
150
2,759
3,023
0
0

3,023

2,759

150

1,165

1,261

150

626

710

150

438

150

260

259

443

624

794

980

1,173

1,366

1,576

1,777

1,979

2,191

2,345

2,567

2,794

3,032

3,267

3,454

3,477

3,606

3,692

3,955

4,150

4,303

4,528

4,672

20,463

21,624

22,467

22,742

23,898

23,937

24,734

26,523

27,341

28,911

26,929

27,959

33,566

37,621

97,868

98,895

101,223

80,022

89,883

159,792

162,255

49,393

51,340

5,538

3,667

> Total Liabilities

0
0
0
588
0
0
0
1,347
0
1,123
0
1,555
0
47,764
0
44,887
0
31,399
0
20,211
14,827
12,995
26,704
25,706
19,837
17,440
15,284
13,563
12,920
10,153
10,339
9,973
9,894
10,100
9,946
9,680
7,908
7,155
7,278
6,961
7,176
7,232
7,879
8,549
8,498
8,220
7,675
7,747
7,938
7,905
7,855
8,999
8,637
9,526
9,612
10,738
10,485
4,984
4,995
5,341
4,326
4,292
41,960
59,983
41,150
40,535
61,977
63,120
63,129
64,993
63,816
65,497
69,197
73,176
71,433
71,958
75,503
78,992
77,736
82,067
84,140
83,988
76,203
118,393
101,422
88,861

88,861

101,422

118,393

76,203

83,988

84,140

82,067

77,736

78,992

75,503

71,958

71,433

73,176

69,197

65,497

63,816

64,993

63,129

63,120

61,977

40,535

41,150

59,983

41,960

4,292

4,326

5,341

4,995

4,984

10,485

10,738

9,612

9,526

8,637

8,999

7,855

7,905

7,938

7,747

7,675

8,220

8,498

8,549

7,879

7,232

7,176

6,961

7,278

7,155

7,908

9,680

9,946

10,100

9,894

9,973

10,339

10,153

12,920

13,563

15,284

17,440

19,837

25,706

26,704

12,995

14,827

20,211

31,399

44,887

47,764

1,555

1,123

1,347

588

> Total Current Liabilities

0
0
0
588
0
0
0
1,347
0
1,123
0
1,555
0
13,629
0
17,792
0
23,889
0
18,086
12,904
11,190
15,897
17,276
13,550
13,108
11,018
8,719
7,259
4,011
3,780
2,934
2,323
1,617
1,492
5,032
3,993
2,634
2,589
3,178
3,462
2,083
2,685
3,303
2,857
2,151
2,276
2,126
2,312
2,273
2,218
3,348
2,993
3,883
3,968
5,093
4,842
4,927
4,940
5,290
4,279
4,250
21,215
21,663
22,418
21,459
24,659
10,721
10,368
11,872
10,298
9,586
12,927
14,888
13,441
16,250
19,933
23,658
31,971
33,390
34,256
34,537
27,242
68,917
63,896
63,263

63,263

63,896

68,917

27,242

34,537

34,256

33,390

31,971

23,658

19,933

16,250

13,441

14,888

12,927

9,586

10,298

11,872

10,368

10,721

24,659

21,459

22,418

21,663

21,215

4,250

4,279

5,290

4,940

4,927

4,842

5,093

3,968

3,883

2,993

3,348

2,218

2,273

2,312

2,126

2,276

2,151

2,857

3,303

2,685

2,083

3,462

3,178

2,589

2,634

3,993

5,032

1,492

1,617

2,323

2,934

3,780

4,011

7,259

8,719

11,018

13,108

13,550

17,276

15,897

11,190

12,904

18,086

23,889

17,792

13,629

1,555

1,123

1,347

588

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,331
0
4,747
0
1,784
0
0
0
2,236
1,466
1,326
1,593
1,552
1,289
1,174
1,048
1,158
912
0
0
1,322
845
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,850
17,309
0
0
417
441
461
481
4,559
0
6,845
8,445
5,915
9,114
11,463
782
10,475
10,475
10,475
10,475
5,295
970
13,417
563

563

13,417

970

5,295

10,475

782

11,463

9,114

5,915

8,445

6,845

4,559

481

461

441

417

17,309

12,850

845

1,322

912

1,158

1,048

1,174

1,289

1,552

1,593

1,326

1,466

2,236

1,784

4,747

8,331

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,850
17,309
0
0
417
0
0
0
0
0
0
0
0
0
0
0
10,475
10,475
10,475
10,475
5,295
0
0
0

5,295

10,475

417

17,309

12,850

Accounts payable

0
0
0
363
0
0
0
808
0
1,117
0
1,494
0
8,061
0
5,506
0
8,624
0
1,316
7,304
7,406
3,385
2,634
737
374
419
284
407
309
472
387
356
219
320
328
511
262
346
394
266
215
355
671
1,082
176
761
464
1,105
384
812
744
893
303
571
1,363
1,015
1,110
741
1,016
1,756
1,483
2,760
6,663
7,418
6,429
9,242
6,066
5,461
11,376
5,158
3,882
5,185
4,811
5,855
5,421
6,639
7,385
7,302
7,058
6,112
5,919
9,453
10,717
9,580
6,504

6,504

9,580

10,717

9,453

5,919

6,112

7,058

7,302

7,385

6,639

5,421

5,855

4,811

5,185

3,882

5,158

11,376

5,461

6,066

9,242

6,429

7,418

6,663

2,760

1,483

1,756

1,016

741

1,110

1,015

1,363

571

303

893

744

812

384

1,105

464

761

176

1,082

671

355

215

266

394

346

262

511

328

320

219

356

387

472

309

407

284

419

374

737

2,634

3,385

7,406

7,304

1,316

8,624

5,506

8,061

1,494

1,117

808

363

Other Current Liabilities

0
0
0
225
0
0
0
539
0
6
0
61
0
540
0
1,974
0
8,787
0
13,286
5,262
3,434
2,262
1,930
600
374
352
971
2,490
2,407
2,181
1,310
972
1,536
1,088
170
128
650
778
608
801
1,084
1,437
1,894
1,087
1,204
1,203
1,524
1,103
1,820
1,371
2,571
2,067
3,552
3,378
3,583
3,688
3,681
3,943
4,224
2,513
2,262
18,215
15,000
15,000
15,000
417
4,214
4,446
6,832
551
5,704
597
687
698
707
796
14,422
13,092
14,720
16,500
16,938
11,257
15,146
1,058
17,604

17,604

1,058

15,146

11,257

16,938

16,500

14,720

13,092

14,422

796

707

698

687

597

5,704

551

6,832

4,446

4,214

417

15,000

18,215

2,262

2,513

4,224

3,943

3,681

3,688

3,583

3,378

3,552

2,067

2,571

1,371

1,820

1,103

1,524

1,203

1,204

1,087

1,894

1,437

1,084

801

608

778

650

128

170

1,088

1,536

972

1,310

2,181

2,407

2,490

971

352

374

600

1,930

2,262

3,434

5,262

13,286

8,787

1,974

540

539

225

> Long-term Liabilities

0
0
0
363
0
0
0
808
0
0
0
1,494
0
0
0
27,094
0
7,510
0
2,125
1,923
1,805
10,807
8,430
6,287
4,332
4,266
4,844
5,661
6,142
6,559
7,039
7,571
8,527
8,454
4,648
3,915
4,521
4,689
3,783
3,714
5,149
5,194
5,246
5,641
6,069
5,399
5,621
5,626
5,632
5,637
5,651
5,644
5,643
5,644
5,645
5,643
57
55
51
47
42
20,745
38,320
18,732
19,076
37,318
52,399
52,761
53,121
53,518
55,911
56,270
58,288
57,992
55,708
55,570
55,334
45,765
48,677
49,884
49,451
48,961
49,476
37,526
25,598

25,598

37,526

49,476

48,961

49,451

49,884

48,677

45,765

55,334

55,570

55,708

57,992

58,288

56,270

55,911

53,518

53,121

52,761

52,399

37,318

19,076

18,732

38,320

20,745

5,643

5,645

5,644

5,643

5,644

5,651

5,637

5,632

5,626

5,621

5,399

6,069

5,641

5,246

5,194

5,149

3,714

3,783

4,689

4,521

3,915

4,648

8,454

8,527

7,571

7,039

6,559

6,142

5,661

4,844

4,266

4,332

6,287

8,430

10,807

1,805

1,923

2,125

7,510

27,094

1,494

808

363

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,850
17,309
17,463
17,621
31,952
46,250
46,733
47,223
47,716
50,259
50,775
37,977
38,124
36,235
36,396
36,562
29,108
29,181
29,251
29,310
29,370
0
0
0

29,370

29,310

29,251

29,181

29,108

36,562

36,396

36,235

38,124

37,977

50,775

50,259

47,716

47,223

46,733

46,250

31,952

17,621

17,463

17,309

12,850

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,275
1,173
10,191
8,114
5,971
4,016
4,013
4,622
5,439
5,920
6,337
6,817
7,349
8,305
8,322
4,635
3,915
4,521
4,689
3,783
3,714
5,149
5,194
5,246
5,641
6,069
5,399
5,621
5,626
5,632
5,637
5,651
5,644
5,643
5,644
5,645
5,643
57
55
51
47
42
7,895
21,011
1,269
1,455
2,100
3,000
3,000
3,000
3,000
3,000
3,000
17,981
17,643
17,425
17,155
16,912
14,942
14,670
14,398
14,157
13,870
44,021
0
0

44,021

13,870

14,157

14,398

14,670

14,942

16,912

17,155

17,425

17,643

17,981

3,000

2,100

1,455

1,269

21,011

7,895

5,643

5,645

5,644

5,643

5,644

5,651

5,637

5,632

5,626

5,621

5,399

6,069

5,641

5,246

5,194

5,149

3,714

3,783

4,689

4,521

3,915

4,635

8,322

8,305

7,349

6,817

6,337

5,920

5,439

4,622

4,013

4,016

5,971

8,114

10,191

1,173

1,275

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,915
4,521
4,689
3,783
3,714
5,149
5,194
5,246
5,641
6,069
5,399
5,621
5,626
5,632
5,637
5,651
5,644
5,643
5,644
5,645
5,643
57
55
51
47
42
6,957
19,780
0
0
0
0
0
0
0
0
0
15,616
15,349
15,132
14,792
14,560
14,302
14,070
13,798
13,557
13,270
44,021
0
0

44,021

13,270

13,557

13,798

14,070

14,302

14,560

14,792

15,132

15,349

15,616

19,780

6,957

5,643

5,645

5,644

5,643

5,644

5,651

5,637

5,632

5,626

5,621

5,399

6,069

5,641

5,246

5,194

5,149

3,714

3,783

4,689

4,521

3,915

> Total Stockholder Equity

0
0
0
4,095
0
0
0
25,604
0
69,024
0
60,743
0
138,934
0
129,962
0
66,201
0
65,907
101,500
94,675
89,162
30,078
27,324
21,791
21,087
23,541
21,572
22,477
19,579
33,041
31,106
28,544
36,994
37,433
35,232
17,793
15,555
13,636
16,163
13,810
11,241
7,700
14,237
12,599
18,346
14,924
35,802
32,275
27,847
23,368
18,823
14,424
26,553
20,881
14,448
14,762
12,510
13,336
9,001
9,905
8,198
11,687
47,705
37,633
19,877
28,210
15,938
8,330
16,474
4,188
7,594
18,541
115,707
106,865
92,748
184,380
166,819
151,366
136,350
96,368
78,390
57,262
58,621
266,323

266,323

58,621

57,262

78,390

96,368

136,350

151,366

166,819

184,380

92,748

106,865

115,707

18,541

7,594

4,188

16,474

8,330

15,938

28,210

19,877

37,633

47,705

11,687

8,198

9,905

9,001

13,336

12,510

14,762

14,448

20,881

26,553

14,424

18,823

23,368

27,847

32,275

35,802

14,924

18,346

12,599

14,237

7,700

11,241

13,810

16,163

13,636

15,555

17,793

35,232

37,433

36,994

28,544

31,106

33,041

19,579

22,477

21,572

23,541

21,087

21,791

27,324

30,078

89,162

94,675

101,500

65,907

66,201

129,962

138,934

60,743

69,024

25,604

4,095

Common Stock

0
0
0
10,482
0
0
0
34,716
0
84,203
0
81,927
0
165,121
0
171,009
0
183,774
0
207,214
247,462
247,810
247,872
18
18
18
18
18
248,811
249,715
250,422
19
19
251,714
21
262,927
263,518
263,683
21
264,452
269,463
269,726
23
270,438
280,597
282,443
29
29
29
291,854
29
293,089
29
294,315
34
312,242
312,985
313,381
316,268
323,323
40
331,654
54
374,840
443,766
445,287
446,769
106
108
472,776
494,094
125
501,965
528,380
29
29
641,572
752,636
34
760,243
763,596
766,933
770,062
771,855
785,827
49

785,827

771,855

770,062

766,933

763,596

760,243

752,636

641,572

528,380

501,965

125

494,094

472,776

108

106

446,769

445,287

443,766

374,840

331,654

323,323

316,268

313,381

312,985

312,242

294,315

293,089

291,854

282,443

280,597

270,438

269,726

269,463

264,452

263,683

263,518

262,927

251,714

250,422

249,715

248,811

247,872

247,810

247,462

207,214

183,774

171,009

165,121

81,927

84,203

34,716

10,482

Retained Earnings Total Equity

-715,435

-692,515

-671,351

-627,899

-609,479

-590,073

-569,097

-549,665

-532,970

-522,960

-510,680

-495,211

-491,410

-478,460

-465,286

-454,876

-439,229

-427,731

-396,899

-363,991

-329,563

-322,585

-316,803

-310,820

-304,582

-299,442

-299,375

-292,213

-285,826

-280,785

-275,599

-270,666

-265,520

-260,522

-256,447

-277,013

-273,046

-270,859

-267,345

-263,658

-259,711

-256,917

-254,309

-251,758

-249,496

-246,810

-229,350

Accumulated Other Comprehensive Income

0
0
0
0
0
0
0
54
0
0
0
16
0
0
0
1,176
0
6,629
0
10,910
8,197
7,038
6,964
6,969
4,592
-285
-617
2,071
1,400
1,425
525
521
1,243
928
1,445
1,429
1,064
920
989
942
1,009
1,001
914
920
985
1,015
1,019
1,044
991
943
899
945
919
894
882
852
838
823
824
833
837
836
837
838
838
839
839
840
840
840
840
840
840
841
841
841
841
841
788
602
653
786
843
842
841
864

864

841

842

843

786

653

602

788

841

840

839

838

837

836

837

833

824

823

838

852

882

894

919

945

899

943

991

1,044

1,019

1,015

985

920

914

1,001

1,009

942

989

920

1,064

1,429

1,445

928

1,243

521

525

1,425

1,400

2,071

-617

-285

4,592

6,969

6,964

7,038

8,197

10,910

6,629

1,176

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
263,497
263,662
264,041
264,431
269,440
269,703
270,015
270,415
280,570
282,416
290,344
290,864
291,229
291,825
292,439
293,060
293,474
294,286
311,463
312,208
312,951
313,347
316,233
323,284
324,927
331,609
336,870
374,766
443,671
445,192
446,673
466,493
469,866
472,667
493,969
494,633
501,834
528,362
637,797
638,965
641,543
752,602
756,070
760,209
763,562
766,899
770,028
771,821
0
0

771,821

770,028

766,899

763,562

760,209

756,070

752,602

641,543

638,965

637,797

528,362

501,834

494,633

493,969

472,667

469,866

466,493

446,673

445,192

443,671

374,766

336,870

331,609

324,927

323,284

316,233

313,347

312,951

312,208

311,463

294,286

293,474

293,060

292,439

291,825

291,229

290,864

290,344

282,416

280,570

270,415

270,015

269,703

269,440

264,431

264,041

263,662

263,497

Treasury Stock

Other Stockholders Equity

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
171,055
0
184,100
0
206,947
242,746
243,094
243,156
247,646
247,740
247,936
248,200
248,500
248,793
249,697
250,403
250,796
251,247
0
262,311
262,906
263,497
263,662
264,041
264,431
269,440
269,703
270,015
270,415
280,570
282,416
290,344
290,864
291,229
291,825
292,439
293,060
293,474
294,286
311,463
312,208
312,951
313,347
316,233
323,284
324,927
331,609
336,870
374,766
443,671
839
446,673
466,493
469,866
472,667
493,969
494,633
501,834
528,362
637,797
638,965
641,543
752,602
756,070
760,209
763,562
767,685
770,028
771,821
0
1,007,556

1,007,556

771,821

770,028

767,685

763,562

760,209

756,070

752,602

641,543

638,965

637,797

528,362

501,834

494,633

493,969

472,667

469,866

466,493

446,673

839

443,671

374,766

336,870

331,609

324,927

323,284

316,233

313,347

312,951

312,208

311,463

294,286

293,474

293,060

292,439

291,825

291,229

290,864

290,344

282,416

280,570

270,415

270,015

269,703

269,440

264,431

264,041

263,662

263,497

262,906

262,311

251,247

250,796

250,403

249,697

248,793

248,500

248,200

247,936

247,740

247,646

243,156

243,094

242,746

206,947

184,100

171,055

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31
Accounts Payable	6,504	5,919	7,385	4,811	11,376	6,663	1,016	1,363	744	464	671	394	328	387	284	2,634	1,316	5,506	1,494	1,494	808	363	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Other Comprehensive Income	864	786	841	841	840	838	833	852	945	1,044	920	942	1,429	521	2,071	6,969	10,910	1,176	16	16	54	0	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Lease Obligations	4,906	6,563	2,642	2,330	3,379	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Stock	49	34	34	18	109	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Surpluse	0	766,899	752,602	528,362	472,667	445,192	374,766	323,284	312,208	293,060	290,864	270,415	264,431	0	0	0	0	0	0	0	0	0	-	-
Cash	281,263	95,633	178,593	44,909	22,214	38,776	16,898	15,313	19,121	15,334	6,899	4,625	12,912	15,514	6,899	15,609	2,668	11,469	9,790	9,790	21,786	793	-	1,643
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Cash And Short Term Investments	331,050	144,561	211,558	44,909	22,214	38,776	16,898	28,992	28,535	18,278	10,273	14,571	24,128	17,565	6,899	15,609	2,668	11,469	9,790	9,790	21,786	793	-	1,643
Common Stock	49	766,933	752,636	528,380	472,776	374,840	323,323	312,242	293,089	29	270,438	264,452	262,927	250,815	18	18	18	207,214	81,927	81,927	34,716	10,482	-	6,179
Common Stock Shares Outstanding	38,904	37,317	28,758	12,836	10,431	4,623	3,534	3,162	3,058	2,744	2,304	2,079	1,949	1,890	1,826	1,817	1,104	752	520	520	12,278	2,536	4,109	-
Common Stock Total Equity	0	34	34	18	109	74	39	34	29	29	23	21	21	19	18	18	0	0	0	81,927	34,716	10,482	-	6,179
Current Deferred Revenue	38,592	1,205	1,069	945	15	0	50	147	33	138	738	2,176	3,212	79	5,912	10,476	1,700	1,981	1,981	0	0	0	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Deferred Long Term Liab	0	13,557	14,560	15,616	0	0	19,780	51	5,645	5,651	5,621	5,246	3,783	0	0	0	0	0	0	0	0	0	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	40,498	39,471	973,923	973,923	0	0	-	-
Intangible Assets	0	0	22,749	25,209	27,669	31,358	364	1,102	1,925	2,765	3,430	4,226	21,564	23,877	28,802	36,802	39,420	120,365	49,237	49,237	5,514	3,626	-	2,608
Inventory	3,906	2,886	3,616	5,337	2,138	-353	-251	-488	-622	0	-597	-967	-843	-1,111	0	0	513	469	469	0	0	0	-	-
Liabilities And Stockholders Equity	355,184	180,356	263,372	91,717	73,323	71,670	18,677	31,619	32,367	22,671	16,249	20,597	47,113	43,014	37,104	55,784	86,118	174,848	62,298	62,298	28,051	4,820	-	4,719
Long Term Debt	0	29,310	36,562	37,977	47,223	17,621	17,309	0	0	0	0	0	0	0	0	0	0	0	2,925	0	0	0	-	-
Long Term Debt Total	0	29,310	36,562	37,977	47,223	17,621	17,309	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Debt	-275,794	-49,864	-140,171	-4,602	28,388	-21,467	-16,898	-15,313	-19,121	-15,334	-6,899	-4,625	-12,912	-15,514	-6,899	-15,609	-2,668	-213	-9,790	-9,790	-21,786	-793	-	-1,497
Net Invested Capital	266,323	136,153	220,942	56,518	55,553	0	28,996	13,336	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Receivables	805	15,503	18,354	9,453	11,720	353	251	488	622	517	597	967	843	1,111	815	1,467	2,508	744	539	539	237	69	-	82
Net Tangible Assets	0	96,368	161,631	-6,668	-19,339	7,504	-19,671	12,972	19,779	21,443	12,159	4,270	9,410	0	0	0	0	0	0	0	0	0	-	-
Net Working Capital	281,537	138,271	214,087	48,230	30,197	18,246	18,246	12,450	26,490	17,216	9,161	12,781	20,334	16,100	-592	414	-12,398	-5,110	9,019	9,019	20,702	291	-	-
Non Current Assets Total	10,384	7,548	25,627	28,599	31,254	31,761	937	1,656	2,529	3,329	3,785	4,638	21,747	23,980	28,977	38,094	80,430	162,166	51,723	51,723	6,002	3,941	-	2,987
Non Current Liabilities Other	0	6,584	4,212	4,695	5,898	0	1,231	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Current Liabilities Total	25,598	49,451	55,334	58,288	53,121	38,320	51	5,645	5,651	5,621	5,246	3,783	4,648	7,039	4,844	8,430	2,125	27,094	1,494	1,494	808	363	-	146
Non Currrent Assets Other	150	1,360	626	150	507	150	260	264	266	267	176	77	60	60	109	819	1	1	0	0	23	43	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Assets	0	150	626	150	150	150	150	260	264	266	267	176	77	60	60	109	0	0	0	0	23	43	-	-
Other Current Assets	9,039	9,858	4,217	3,419	8,135	1,133	842	971	1,303	547	2,191	1,388	1,238	1,469	413	614	-1	0	245	245	27	18	-	6
Other Current Liab	17,604	16,938	14,422	687	6,832	15,000	4,224	3,583	2,571	1,524	1,894	608	170	1,310	971	1,930	13,286	1,974	61	61	539	225	-	146
Other Liab	0	14,157	16,912	17,981	3,000	1,455	21,011	51	5,645	5,651	5,621	5,246	3,783	4,635	6,817	4,622	8,114	0	0	0	0	0	-	-
Other Stockholder Equity	1,007,556	766,899	752,602	528,362	472,667	374,766	323,284	312,208	293,060	290,864	270,415	264,431	262,906	250,796	248,500	247,646	206,947	171,055	171,055	0	0	0	-	703
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Property Plant And Equipment Gross	12,805	6,038	2,252	3,240	3,435	253	313	290	338	297	179	335	123	43	66	473	473	511	2,331	2,486	465	272	-	380
Property Plant And Equipment Net	10,234	6,038	2,252	3,240	3,078	253	313	290	338	297	179	335	123	43	66	473	511	2,331	2,486	2,486	465	272	-	380
Property Plant Equipment	0	1,360	2,252	630	357	288	253	313	290	338	297	179	335	123	43	66	473	512	2,331	2,494	466	271	-	-
Retained Earnings	-742,146	-671,351	-569,097	-510,680	-465,286	-363,991	-310,820	-292,213	-270,666	-277,013	-263,658	-251,758	-226,923	-218,295	-227,048	-224,537	-151,950	-42,269	-21,200	-21,200	-9,166	-6,387	-	-2,308
Retained Earnings Total Equity	0	-671,351	-569,097	-510,680	-465,286	0	-363,991	-310,820	-292,213	-270,666	-277,013	-263,658	-251,758	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt	0	10,475	0	0	0	0	17,309	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt Total	5,469	45,769	38,422	40,307	50,602	17,309	17,309	0	0	0	0	0	0	0	0	0	0	11,256	11,256	0	0	0	-	146
Short Term Debt	563	10,475	782	8,445	481	0	17,309	0	0	0	0	0	1,322	1,158	1,552	2,236	1,784	8,331	8,331	0	0	0	-	-
Short Term Investments	49,787	48,928	32,965	0	0	0	0	13,679	9,414	2,944	3,374	9,946	11,216	2,051	2,051	0	0	0	0	0	0	0	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Assets	355,184	180,356	263,372	91,717	73,323	71,670	18,677	31,619	32,367	22,671	16,249	20,597	47,113	43,014	37,104	55,784	86,118	174,848	62,298	62,298	28,051	4,820	-	4,719
Total Current Assets	344,800	172,808	237,745	63,118	42,069	39,909	17,740	29,963	29,838	19,342	12,464	15,959	25,366	19,034	8,127	17,690	5,688	12,682	10,574	10,574	22,049	880	-	1,732
Total Current Liabilities	63,263	34,537	23,658	14,888	11,872	21,663	5,290	5,093	3,348	2,126	3,303	3,178	5,032	2,934	8,719	17,276	18,086	17,792	1,555	1,555	1,347	588	-	146
Total Liab	88,861	83,988	78,992	73,176	64,993	59,983	5,341	10,738	8,999	7,747	8,549	6,961	9,680	9,973	13,563	25,706	20,211	44,887	1,555	1,555	1,347	588	-	146
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Stockholder Equity	266,323	96,368	184,380	18,541	8,330	11,687	13,336	20,881	23,368	14,924	7,700	13,636	37,433	33,041	23,541	30,078	65,907	129,962	60,743	60,743	25,604	4,095	-	4,573
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30
Accounts Payable	6,504	9,580	10,717	9,453	5,919	6,112	7,058	7,302	7,385	6,639	5,421	5,855	4,811	5,185	3,882	5,158	11,376	5,461	6,066	9,242	6,429	7,418	6,663	2,760	1,483	1,756	1,016	741	1,110	1,015	1,363	571	303	893	744	812	384	1,105	464	761	176	1,082	671	355	215	266	394	346	262	511	328	320	219	356	387	472	309	407	284	419	374	737	2,634	3,385	7,406	7,304	1,316	-	8,624	-	5,506	-	8,061	-	1,494	-	1,117	-	808	-	-	-	363	-	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Accumulated Other Comprehensive Income	864	841	842	843	786	653	602	788	841	841	841	841	841	840	840	840	840	840	840	839	839	838	838	837	836	837	833	824	823	838	852	882	894	919	945	899	943	991	1,044	1,019	1,015	985	920	914	1,001	1,009	942	989	920	1,064	1,429	1,445	928	1,243	521	525	1,425	1,400	2,071	-617	-285	4,592	6,969	6,964	7,038	8,197	10,910	-	6,629	-	1,176	-	0	-	16	-	0	-	54	-	-	-	0	-	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Capital Lease Obligations	4,906	5,185	5,455	5,721	6,563	6,235	4,826	1,697	2,642	2,019	2,013	2,172	2,330	2,483	2,626	2,764	3,379	3,489	3,590	3,683	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Capital Stock	49	785,827	771,855	770,062	34	763,596	760,243	34	34	29	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Capital Surpluse	0	0	771,821	770,028	766,899	763,562	760,209	756,070	752,602	641,543	638,965	637,797	528,362	501,834	494,633	493,969	472,667	469,866	466,493	446,673	445,192	443,671	374,766	336,870	331,609	324,927	323,284	316,233	313,347	312,951	312,208	311,463	294,286	293,474	293,060	292,439	291,825	291,229	290,864	290,344	282,416	280,570	270,415	270,015	269,703	269,440	264,431	264,041	263,662	263,497	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Cash	281,263	133,035	139,597	105,765	95,633	75,362	82,134	101,545	178,593	119,710	127,630	138,579	44,909	28,726	22,814	26,299	22,214	31,760	44,161	43,379	45,261	55,764	38,776	16,346	12,876	11,833	16,898	12,871	11,685	14,308	15,313	24,867	11,210	14,088	19,121	23,007	29,751	11,384	15,334	18,555	15,219	14,546	6,899	7,998	9,409	17,646	4,625	6,375	8,408	9,811	12,912	13,296	7,377	10,126	15,514	3,971	5,129	5,963	6,899	8,019	9,849	10,982	15,609	18,175	9,783	16,454	2,668	-	4,249	-	11,469	-	0	-	9,790	-	0	-	21,786	-	-	-	793	-	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Cash And Short Term Investments	331,050	136,012	142,535	122,483	144,561	157,259	171,167	190,784	211,558	119,710	127,630	138,579	44,909	28,726	22,814	26,299	22,214	31,760	44,161	43,379	45,261	55,764	38,776	16,346	12,876	11,833	16,898	15,370	17,532	22,546	28,992	33,274	21,091	24,005	28,535	31,658	35,686	14,308	18,278	21,267	15,721	16,454	10,273	13,697	15,720	17,646	14,571	16,462	18,680	21,271	24,128	23,066	7,377	15,319	17,565	3,971	5,129	5,963	6,899	8,019	9,849	10,982	15,609	18,175	9,783	16,454	2,668	-	4,249	-	11,469	-	0	-	9,790	-	0	-	21,786	-	-	-	793	-	-	-
Common Stock	49	785,827	771,855	770,062	766,933	763,596	760,243	34	752,636	641,572	29	29	528,380	501,965	125	494,094	472,776	108	106	446,769	445,287	443,766	374,840	54	331,654	40	323,323	316,268	313,381	312,985	312,242	34	294,315	29	293,089	29	291,854	29	29	29	282,443	280,597	270,438	23	269,726	269,463	264,452	21	263,683	263,518	262,927	21	251,714	19	19	250,422	249,715	248,811	18	18	18	18	18	247,872	247,810	247,462	207,214	-	183,774	-	171,009	-	165,121	-	81,927	-	84,203	-	34,716	-	-	-	10,482	-	-	-
Common Stock Shares Outstanding	42,168	38,341	37,576	37,486	37,352	37,338	37,322	37,253	32,700	28,766	28,744	24,735	14,501	12,794	12,477	11,553	10,668	10,694	10,624	9,545	9,494	7,517	5,539	4,564	4,453	3,943	3,867	3,437	3,418	3,418	3,415	3,354	2,944	2,942	2,941	2,941	2,937	3,077	3,077	2,767	2,695	2,592	2,330	2,330	2,330	2,229	2,080	2,080	2,080	2,076	2,075	2,018	1,853	1,853	18,895	1,848	1,832	1,829	18,166	1,826	1,826	1,826	18,166	18,263	18,263	17,898	17,898	44,798	9,978	10	10	968	968	968	968	20,764	20,770	20,776	20,776	12,271	12,262	12,279	12,279	9,226	9,212	9,223
Common Stock Total Equity	0	0	34	34	34	34	34	34	34	29	29	29	18	131	125	125	109	108	106	96	445,287	95	74	54	45	40	39	35	34	34	34	34	29	29	29	29	29	29	29	29	27	27	23	23	23	23	21	21	21	21	21	21	251,714	19	19	19	18	18	18	18	18	0	0	0	0	0	0	-	0	-	0	-	0	-	81,927	-	0	-	34,716	-	-	-	10,482	-	-	-
Current Deferred Revenue	38,592	39,841	42,084	1,237	1,205	1,169	1,137	1,102	1,069	1,035	1,008	973	945	300	0	30	15	0	0	14,583	30	0	0	240	505	10	50	256	136	139	147	19	28	33	33	35	69	104	138	312	771	688	738	893	784	2,395	2,176	1,465	1,722	2,509	3,212	84	81	83	79	79	121	3,073	5,912	8,654	11,034	10,747	10,476	10,250	350	338	1,700	-	1,731	-	1,981	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Deferred Long Term Liab	0	0	44,021	13,270	13,557	13,798	14,070	14,302	14,560	14,792	15,132	15,349	15,616	0	0	0	0	0	0	0	0	0	19,780	6,957	42	47	51	55	57	5,643	5,645	5,644	5,643	5,644	5,651	5,637	5,632	5,626	5,621	5,399	6,069	5,641	5,246	5,194	5,149	3,714	3,783	4,689	4,521	3,915	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	56,042	55,386	55,413	56,042	40,498	-	40,142	-	39,471	-	39,119	-	973,923	-	0	-	0	-	-	-	0	-	-	-
Intangible Assets	0	0	0	0	0	20,904	21,519	22,134	22,749	23,364	23,979	24,594	25,209	25,824	26,439	27,054	27,669	28,284	28,899	29,514	30,129	30,743	31,358	31,973	0	184	364	540	718	910	1,102	1,311	1,512	1,713	1,925	2,080	2,301	2,528	2,765	2,940	3,127	3,300	3,430	3,619	3,883	4,078	4,226	4,451	4,596	20,387	21,564	22,406	22,681	23,838	23,877	24,674	26,438	27,257	28,802	26,796	27,899	33,507	36,802	37,766	38,766	40,465	39,420	-	49,900	-	120,365	-	162,255	-	49,237	-	51,328	-	5,514	-	-	-	3,626	-	-	-
Inventory	3,906	4,577	4,261	4,071	2,886	3,531	3,254	3,336	3,616	4,571	5,381	5,586	5,337	3,642	3,773	3,358	2,138	2,559	1,670	886	-288	-489	-353	0	-288	0	-251	-300	-457	-462	-488	0	-573	0	-622	0	-727	0	0	0	-636	-1,112	-597	0	-948	-938	0	0	0	0	0	0	0	0	0	-713	-788	-833	0	0	0	0	0	-4,231	-3,362	-2,899	513	-	0	-	469	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Liabilities And Stockholders Equity	355,184	160,043	175,655	154,593	180,356	220,490	233,433	244,555	263,372	168,251	178,823	187,140	91,717	76,791	69,685	80,290	73,323	79,067	91,330	81,854	78,168	88,855	71,670	50,158	14,197	13,327	18,677	17,505	19,746	24,933	31,619	36,165	23,950	27,460	32,367	35,702	40,180	43,740	22,671	26,021	20,819	22,735	16,249	19,120	21,042	23,339	20,597	22,833	24,948	43,140	47,113	46,940	38,644	41,000	43,014	29,918	32,630	34,492	37,104	36,371	39,231	47,161	55,784	115,866	107,670	116,327	86,118	-	97,600	-	174,848	-	0	-	62,298	-	0	-	28,051	-	-	-	4,820	-	-	-
Long Term Debt	0	0	0	29,370	29,310	29,251	29,181	29,108	36,562	36,396	36,235	38,124	37,977	50,775	50,259	47,716	47,223	46,733	46,250	31,952	17,621	17,463	17,309	12,850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	4,312	-	2,925	-	8,402	-	0	-	0	-	0	-	-	-	0	-	-	-
Long Term Debt Total	0	0	0	29,370	29,310	29,251	29,181	29,108	36,562	36,396	36,235	38,124	37,977	50,775	50,259	47,716	47,223	46,733	46,250	31,952	17,621	17,463	17,309	12,850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Net Debt	-275,794	-127,850	-134,142	-65,379	-49,864	-29,401	-37,652	-60,265	-140,171	-81,295	-89,382	-98,283	-4,602	24,532	30,071	24,181	28,388	18,462	5,679	-7,744	-27,640	-38,301	-21,467	-3,496	-12,876	-11,833	-16,898	-12,871	-11,685	-14,308	-15,313	-24,867	-11,210	-14,088	-19,121	-23,007	-29,751	-11,384	-15,334	-18,555	-15,219	-14,546	-6,899	-7,998	-9,409	-17,646	-4,625	-6,375	-8,408	-9,811	-12,912	-13,296	-7,377	-10,126	-15,514	-3,971	-5,129	-5,963	-6,899	-8,019	-9,849	-10,982	-15,609	-18,175	-9,783	-16,454	-2,668	-	4,819	-	-213	-	0	-	-9,790	-	0	-	-21,786	-	-	-	-793	-	-	-
Net Invested Capital	266,323	58,621	57,262	113,055	136,153	176,076	191,022	206,402	220,942	129,144	143,100	153,831	56,518	58,369	54,447	64,190	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Net Receivables	805	483	10,952	10,422	15,503	20,876	22,594	19,589	18,354	13,602	15,111	12,332	9,453	9,392	7,350	14,390	11,720	8,855	9,598	2,258	288	489	353	478	288	287	251	300	457	462	488	472	573	569	622	430	727	25,462	517	613	636	1,112	597	1,035	948	938	967	985	1,016	723	843	832	1,094	1,487	1,111	713	788	833	815	879	885	1,829	1,467	4,231	3,362	2,899	2,508	-	1,621	-	744	-	0	-	539	-	0	-	237	-	-	-	69	-	-	-
Net Tangible Assets	0	0	57,262	78,390	96,368	115,446	129,847	144,685	161,631	69,384	82,886	91,113	-6,668	-18,230	-22,251	-10,580	-19,339	-12,346	-689	19,877	7,504	16,962	-19,671	-23,775	9,905	8,817	12,972	11,970	14,044	13,538	19,779	25,242	12,912	17,110	21,443	25,767	29,974	33,274	12,159	15,406	9,472	10,937	4,270	7,622	9,927	12,085	9,410	11,104	13,197	14,845	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Net Working Capital	281,537	86,267	98,201	118,815	138,271	157,846	172,476	187,658	214,087	121,842	135,576	145,912	48,230	34,665	30,246	39,396	30,197	36,693	47,852	23,713	26,142	35,224	18,246	-3,540	9,395	8,268	12,450	11,530	13,608	18,661	24,870	30,310	17,979	22,170	26,490	30,859	35,075	38,373	17,216	20,186	15,081	16,255	9,161	12,520	14,727	15,438	12,781	15,306	17,219	18,287	20,334	22,846	14,241	14,729	16,100	1,352	2,049	-163	-592	-1,651	-2,202	-369	414	6,509	1,955	6,449	-12,398	-	-17,725	-	-5,110	-	0	-	9,019	-	0	-	20,702	-	-	-	291	-	-	-
Non Current Assets Total	10,384	9,880	8,537	8,536	7,548	28,388	27,567	24,926	25,627	26,476	26,997	27,787	28,599	29,199	29,853	30,596	31,254	32,006	32,757	33,482	30,567	31,213	31,761	32,483	552	780	937	1,035	1,211	1,430	1,656	1,887	2,088	2,297	2,529	2,625	2,832	3,055	3,329	3,559	3,587	3,623	3,785	3,915	4,232	4,439	4,638	4,938	5,095	20,860	21,747	22,602	22,830	23,948	23,980	24,786	26,570	27,396	28,977	27,004	28,325	33,980	38,094	93,460	94,525	96,974	80,430	-	91,436	-	162,166	-	0	-	51,723	-	0	-	6,002	-	-	-	3,941	-	-	-
Non Current Liabilities Other	0	0	5,455	6,321	6,584	6,835	5,426	2,355	4,212	4,382	2,328	4,519	4,695	5,495	5,652	5,802	5,898	6,028	6,149	2,100	0	1,269	1,231	938	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Non Current Liabilities Total	25,598	37,526	49,476	48,961	49,451	49,884	48,677	45,765	55,334	55,570	55,708	57,992	58,288	56,270	55,911	53,518	53,121	52,761	52,399	37,318	19,076	18,732	38,320	20,745	42	47	51	55	57	5,643	5,645	5,644	5,643	5,644	5,651	5,637	5,632	5,626	5,621	5,399	6,069	5,641	5,246	5,194	5,149	3,714	3,783	4,689	4,521	3,915	4,648	8,454	8,527	7,571	7,039	6,559	6,142	5,661	4,844	4,266	4,332	6,287	8,430	10,807	1,805	1,923	2,125	-	7,510	-	27,094	-	0	-	1,494	-	0	-	808	-	-	-	363	-	-	-
Non Currrent Assets Other	150	4,480	2,873	2,609	1,360	1,165	1,261	150	626	710	150	150	150	642	150	575	507	150	150	575	438	149	150	260	259	259	260	254	262	263	264	265	265	266	266	265	266	266	267	327	327	177	176	73	72	72	77	77	76	76	60	61	61	60	60	60	85	84	109	133	60	59	819	0	0	0	1	-	0	-	0	-	0	-	0	-	0	-	23	-	-	-	43	-	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Other Assets	0	0	3,023	2,759	150	1,165	1,261	150	626	710	150	150	150	150	150	150	150	150	150	150	438	150	150	260	259	443	624	794	980	1,173	1,366	1,576	1,777	1,979	2,191	2,345	2,567	2,794	3,032	3,267	3,454	3,477	3,606	3,692	3,955	4,150	4,303	4,528	4,672	20,463	21,624	22,467	22,742	23,898	23,937	24,734	26,523	27,341	28,911	26,929	27,959	33,566	37,621	97,868	98,895	101,223	80,022	-	89,883	-	159,792	-	162,255	-	49,393	-	51,340	-	5,538	-	-	-	3,667	-	-	-
Other Current Assets	9,039	9,091	9,370	9,081	9,858	10,436	8,851	5,920	4,217	3,892	3,704	2,856	3,419	5,832	5,895	5,647	8,135	3,887	3,144	2,735	2,340	1,878	1,133	851	769	427	842	1,100	1,003	957	971	532	771	589	1,303	989	1,662	915	547	582	1,511	2,658	2,191	473	1,090	1,254	421	448	157	286	395	440	7,387	246	358	1,161	931	1,133	413	469	172	370	614	4,231	3,362	2,899	-1	-	294	-	0	-	378	-	245	-	73	-	27	-	-	-	18	-	-	-
Other Current Liab	17,604	1,058	15,146	11,257	16,938	16,500	14,720	13,092	14,422	796	707	698	687	597	5,704	551	6,832	4,446	4,214	417	15,000	15,000	15,000	18,215	2,262	2,513	4,224	3,943	3,681	3,688	3,583	3,378	3,552	2,067	2,571	1,371	1,820	1,103	1,524	1,203	1,204	1,087	1,894	1,437	1,084	801	608	778	650	128	170	1,088	1,536	972	1,310	2,181	2,407	2,490	971	352	374	600	1,930	2,262	3,434	5,262	13,286	-	8,787	-	1,974	-	540	-	61	-	6	-	539	-	-	-	225	-	-	-
Other Liab	0	0	44,021	13,870	14,157	14,398	14,670	14,942	16,912	17,155	17,425	17,643	17,981	3,000	3,000	3,000	3,000	3,000	3,000	2,100	1,455	1,269	21,011	7,895	42	47	51	55	57	5,643	5,645	5,644	5,643	5,644	5,651	5,637	5,632	5,626	5,621	5,399	6,069	5,641	5,246	5,194	5,149	3,714	3,783	4,689	4,521	3,915	4,635	8,322	8,305	7,349	6,817	6,337	5,920	5,439	4,622	4,013	4,016	5,971	8,114	10,191	1,173	1,275	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Other Stockholder Equity	1,007,556	0	771,821	770,028	767,685	763,562	760,209	756,070	752,602	641,543	638,965	637,797	528,362	501,834	494,633	493,969	472,667	469,866	466,493	446,673	839	443,671	374,766	336,870	331,609	324,927	323,284	316,233	313,347	312,951	312,208	311,463	294,286	293,474	293,060	292,439	291,825	291,229	290,864	290,344	282,416	280,570	270,415	270,015	269,703	269,440	264,431	264,041	263,662	263,497	262,906	262,311	0	251,247	250,796	250,403	249,697	248,793	248,500	248,200	247,936	247,740	247,646	243,156	243,094	242,746	206,947	-	184,100	-	171,055	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Property Plant And Equipment Gross	12,805	5,250	5,514	5,777	6,038	6,319	0	0	0	0	2,868	3,043	3,240	3,225	3,264	3,392	3,435	3,572	3,708	3,818	0	320	253	250	293	337	313	241	231	257	290	311	311	318	338	280	265	261	297	292	133	146	179	223	277	289	335	410	423	397	123	135	88	50	43	52	47	55	66	75	366	414	473	467	346	467	511	-	1,393	-	2,331	-	0	-	2,486	-	0	-	465	-	-	-	272	-	-	-
Property Plant And Equipment Net	10,234	5,250	5,514	5,777	6,038	6,319	4,787	2,642	2,252	2,402	2,868	3,043	3,240	2,733	3,264	2,967	3,078	3,572	3,708	3,393	0	320	253	250	293	337	313	241	231	257	290	311	311	318	338	280	265	261	297	292	133	146	179	223	277	289	335	410	423	397	123	135	88	50	43	52	47	55	66	75	366	414	473	308	346	467	511	-	1,393	-	2,331	-	0	-	2,486	-	0	-	465	-	-	-	272	-	-	-
Property Plant Equipment	0	0	2,873	2,609	1,360	1,015	4,787	545	2,252	2,402	2,868	559	630	492	412	425	357	386	417	425	288	320	253	250	293	337	313	241	231	257	290	311	311	318	338	280	265	261	297	292	133	146	179	223	277	289	335	410	423	397	123	135	88	50	43	52	47	55	66	75	366	414	473	308	346	467	512	-	1,391	-	2,331	-	2,830	-	2,494	-	1,371	-	466	-	-	-	271	-	-	-
Retained Earnings	-742,146	-728,047	-715,435	-692,515	-671,351	-627,899	-609,479	-590,073	-569,097	-549,665	-532,970	-522,960	-510,680	-495,211	-491,410	-478,460	-465,286	-454,876	-439,229	-427,731	-408,493	-396,899	-363,991	-329,563	-322,585	-316,803	-310,820	-304,582	-299,442	-299,375	-292,213	-285,826	-280,785	-275,599	-270,666	-265,520	-260,522	-256,447	-277,013	-273,046	-270,859	-267,345	-263,658	-259,711	-256,917	-254,309	-251,758	-249,496	-246,810	-229,350	-226,923	-226,783	-224,098	-221,403	-218,295	-231,368	-228,663	-228,639	-227,048	-226,514	-225,878	-225,008	-224,537	-160,958	-155,457	-149,443	-151,950	-	-124,528	-	-42,269	-	0	-	-21,200	-	0	-	-9,166	-	-	-	-6,387	-	-	-
Retained Earnings Total Equity	0	0	-715,435	-692,515	-671,351	-627,899	-609,479	-590,073	-569,097	-549,665	-532,970	-522,960	-510,680	-495,211	-491,410	-478,460	-465,286	-454,876	-439,229	-427,731	0	-396,899	-363,991	-329,563	-322,585	-316,803	-310,820	-304,582	-299,442	-299,375	-292,213	-285,826	-280,785	-275,599	-270,666	-265,520	-260,522	-256,447	-277,013	-273,046	-270,859	-267,345	-263,658	-259,711	-256,917	-254,309	-251,758	-249,496	-246,810	-229,350	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Short Long Term Debt	0	0	0	5,295	10,475	10,475	10,475	10,475	0	0	0	0	0	0	0	0	0	0	0	417	0	0	17,309	12,850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Short Long Term Debt Total	5,469	5,185	5,455	40,386	45,769	45,961	44,482	41,280	38,422	38,415	38,248	40,296	40,307	53,258	52,885	50,480	50,602	50,222	49,840	35,635	17,621	17,463	17,309	12,850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	9,068	-	11,256	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Short Term Debt	563	13,417	970	5,295	10,475	10,475	10,475	10,475	782	11,463	9,114	5,915	8,445	6,845	0	4,559	481	461	441	417	0	0	17,309	12,850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	845	1,322	0	0	912	1,158	1,048	1,174	1,289	1,552	1,593	1,326	1,466	2,236	0	0	0	1,784	-	4,747	-	8,331	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Short Term Investments	49,787	2,977	2,938	16,718	48,928	81,897	89,033	89,239	32,965	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,499	5,847	8,238	13,679	8,407	9,881	9,917	9,414	8,651	5,935	2,924	2,944	2,712	502	1,908	3,374	5,699	6,311	9,258	9,946	10,087	10,272	11,460	11,216	9,770	7,266	5,193	2,051	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Total Assets	355,184	160,043	175,655	154,593	180,356	220,490	233,433	244,555	263,372	168,251	178,823	187,140	91,717	76,791	69,685	80,290	73,323	79,067	91,330	81,854	78,168	88,855	71,670	50,158	14,197	13,327	18,677	17,505	19,746	24,933	31,619	36,165	23,950	27,460	32,367	35,702	40,180	43,740	22,671	26,021	20,819	22,735	16,249	19,120	21,042	23,339	20,597	22,833	24,948	43,140	47,113	46,940	38,688	41,000	43,014	29,918	32,630	34,492	37,104	36,371	39,231	47,161	55,784	115,866	107,670	116,327	86,118	-	97,600	-	174,848	-	186,698	-	62,298	-	70,147	-	28,051	-	-	-	4,820	-	-	-
Total Current Assets	344,800	150,163	167,118	146,057	172,808	192,102	205,866	219,629	237,745	141,775	151,826	159,353	63,118	47,592	39,832	49,694	42,069	47,061	58,573	48,372	47,601	57,642	39,909	17,675	13,645	12,547	17,740	16,470	18,535	23,503	29,963	34,278	21,862	25,163	29,838	33,077	37,348	40,685	19,342	22,462	17,232	19,112	12,464	15,205	16,810	18,900	15,959	17,895	19,853	22,280	25,366	24,338	15,858	17,052	19,034	5,132	6,060	7,096	8,127	9,367	10,906	13,181	17,690	22,406	13,145	19,353	5,688	-	6,164	-	12,682	-	0	-	10,574	-	0	-	22,049	-	-	-	880	-	-	-
Total Current Liabilities	63,263	63,896	68,917	27,242	34,537	34,256	33,390	31,971	23,658	19,933	16,250	13,441	14,888	12,927	9,586	10,298	11,872	10,368	10,721	24,659	21,459	22,418	21,663	21,215	4,250	4,279	5,290	4,940	4,927	4,842	5,093	3,968	3,883	2,993	3,348	2,218	2,273	2,312	2,126	2,276	2,151	2,857	3,303	2,685	2,083	3,462	3,178	2,589	2,634	3,993	5,032	1,492	1,617	2,323	2,934	3,780	4,011	7,259	8,719	11,018	13,108	13,550	17,276	15,897	11,190	12,904	18,086	-	23,889	-	17,792	-	13,629	-	1,555	-	1,123	-	1,347	-	-	-	588	-	-	-
Total Liab	88,861	101,422	118,393	76,203	83,988	84,140	82,067	77,736	78,992	75,503	71,958	71,433	73,176	69,197	65,497	63,816	64,993	63,129	63,120	61,977	40,535	41,150	59,983	41,960	4,292	4,326	5,341	4,995	4,984	10,485	10,738	9,612	9,526	8,637	8,999	7,855	7,905	7,938	7,747	7,675	8,220	8,498	8,549	7,879	7,232	7,176	6,961	7,278	7,155	7,908	9,680	9,946	10,100	9,894	9,973	10,339	10,153	12,920	13,563	15,284	17,440	19,837	25,706	26,704	12,995	14,827	20,211	-	31,399	-	44,887	-	47,764	-	1,555	-	1,123	-	1,347	-	-	-	588	-	-	-
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Total Stockholder Equity	266,323	58,621	57,262	78,390	96,368	136,350	151,366	166,819	184,380	92,748	106,865	115,707	18,541	7,594	4,188	16,474	8,330	15,938	28,210	19,877	37,633	47,705	11,687	8,198	9,905	9,001	13,336	12,510	14,762	14,448	20,881	26,553	14,424	18,823	23,368	27,847	32,275	35,802	14,924	18,346	12,599	14,237	7,700	11,241	13,810	16,163	13,636	15,555	17,793	35,232	37,433	36,994	28,544	31,106	33,041	19,579	22,477	21,572	23,541	21,087	21,791	27,324	30,078	89,162	94,675	101,500	65,907	-	66,201	-	129,962	-	138,934	-	60,743	-	69,024	-	25,604	-	-	-	4,095	-	-	-
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31
Begin Period Cash Flow	95,633	178,743	45,059	22,364	45,411	17,048	15,313	19,121	15,334	6,899	4,625	12,912	15,514	6,899	15,609	2,670	13,099	9,572	23,808	23,808	820	3,394
Capital Expenditures	3,483	2,150	156	362	213	108	147	113	161	248	68	405	133	15	195	272	82	1,154	2,590	2,590	366	36
Cash And Cash Equivalents Changes	0	-82,960	133,684	22,695	-23,048	0	21,876	1,585	-3,808	3,787	8,435	2,274	-8,287	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	-1,357	-331	17,363	627	0	15	-108	192	-118	1,147	-1,272	-756	0	0	0	0	0	0	0	0	0
Change In Cash	185,630	-82,960	133,684	22,695	-23,047	21,878	1,585	-3,808	3,787	8,435	2,274	-8,287	-2,602	8,615	-8,710	12,939	-10,431	1,897	-14,017	-14,017	20,965	-2,601
Change In Working Capital	58,882	-3,023	-1,739	20,136	-12,536	925	318	2,073	1,009	389	692	-2,715	1,211	-4,015	-10,452	13,455	147	2,189	-339	-339	564	259
Change Receivables	0	-2,662	-10,603	4,846	-15,304	0	7	219	116	-124	103	364	-128	0	0	0	0	0	0	0	0	0
Change To Account Receivables	14,432	-2,662	-10,603	4,846	-15,304	7	219	116	-124	103	364	-128	285	-290	-290	124	0	0	207	0	0	25
Change To Inventory	-1,553	-760	1,347	-3,200	-1,859	-759	551	1,223	917	729	16	-756	110	-308	0	0	0	0	0	0	0	0
Change To Liabilities	0	1,198	7,545	1,872	4,596	1,980	1,112	207	1,765	1,251	-861	1,600	-1,831	82	0	0	0	0	0	170	738	271
Change To Netincome	0	38,384	6,660	7,429	9,430	49,131	28,982	2,456	2,163	1,961	1,333	1,317	16,058	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	69	-28	72	46	213	-20	-9	1,228	935	766	0	0	0	0	0	0	0	0	0	0	0
Depreciation	464	2,446	2,771	2,649	2,604	1,148	815	908	882	917	994	2,227	3,355	3,326	3,438	397	8,718	8,699	1,242	1,242	241	212
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	281,263	95,783	178,743	45,059	22,364	38,926	16,898	15,313	19,121	15,334	6,899	4,625	12,912	15,514	6,899	15,609	2,668	11,469	9,790	9,790	21,786	793
Exchange Rate Changes	0	0	0	0	0	0	0	-5	-20	-12	-4	-8	-6	0	0	0	0	0	0	0	0	0
Free Cash Flow	-1,608	-67,155	-50,253	-14,797	-56,912	-22,015	-20,637	-16,429	10,136	-10,919	-8,813	-9,406	-3,303	9,884	-8,631	-5,415	-21,297	-17,293	-11,934	-11,934	-5,801	-3,096
Investments	-3,315	-15,115	-32,965	-362	-213	-32,965	-16,888	13,691	-4,349	-6,572	386	6,426	1,011	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	226,174	108,476	216,825	49,918	22,627	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-653	-146	-14,622	25,943	20,000	18,653	20,000	20,000	20,000	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-70,795	-102,254	-58,417	-45,394	-56,793	-53,171	-18,485	-21,547	6,347	-13,355	-11,900	-24,835	-8,628	8,753	-2,511	-75,670	-103,675	-20,913	-11,486	-11,486	-5,225	-3,598
Other Cashflows From Financing Activities	-1,970	70,687	223	1,417	31,237	19,156	99	490	235	987	6,358	114	17	802	-195	-2,237	-17,353	12,783	-21	-21	311	-32
Other Cashflows From Investing Activities	0	0	0	0	0	0	-16,780	33	-4,349	0	-72	0	0	0	0	0	0	1,856	0	0	0	0
Other Non Cash Items	1,184	23,649	628	1,722	1,648	209	-5,594	87	98	45	152	14,924	-951	339	311	57,223	92,287	1,450	1,240	1,240	-1,016	67
Sale Purchase Of Stock	0	-295	-150	-90	-120	29,399	42,018	8,503	16,990	235	987	4,669	114	0	0	0	0	0	0	0	0	0
Stock Based Compensation	12,057	14,177	7,447	5,547	4,568	2,704	2,456	2,163	1,961	1,411	1,317	1,411	2,052	1,495	872	-13	4,837	-496	-496	0	0	0
Total Cash From Financing Activities	187,070	-690	216,902	37,492	33,864	60,671	8,503	16,990	235	19,044	4,669	114	10,060	802	802	18,385	10,128	21,653	2,764	2,764	25,679	573
Total Cash From Operating Activities	1,875	-65,005	-50,097	-14,435	-56,699	-21,907	-20,490	-16,316	10,297	-10,671	-8,745	-9,001	-3,170	9,899	-8,436	-5,143	-21,215	-16,139	-9,344	-9,344	-5,435	-3,060
Total Cashflows From Investing Activities	0	-17,265	-33,121	-362	-213	-16,956	-16,888	13,577	-4,462	-6,733	66	6,358	606	0	0	0	0	1,775	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2006-12-31	2006-06-30	2005-12-31	2005-06-30	2004-12-31	2004-06-30	2003-06-30
Begin Period Cash Flow	133,035	139,597	105,915	95,783	75,512	82,284	101,695	178,743	119,860	127,780	138,729	45,059	28,876	22,964	26,449	22,364	31,910	44,311	43,529	45,411	55,764	38,926	16,346	12,876	11,833	16,898	12,871	11,685	14,308	15,313	24,867	11,210	14,088	19,121	23,007	29,751	11,384	15,334	18,555	15,219	14,546	6,899	7,998	9,409	8,388	4,625	6,375	8,408	9,811	12,912	13,296	7,377	10,126	15,514	3,971	5,129	5,963	6,899	8,019	9,849	10,982	15,609	18,175	9,783	16,454	2,670	0	0	0	0	0	0	0	0
Capital Expenditures	883	1,720	396	484	585	1,198	218	149	1,608	131	25	192	192	128	26	16	6	207	25	182	109	109	45	1	64	64	126	16	5	46	46	31	25	11	90	43	22	6	173	54	13	8	19	13	32	4	6	19	159	221	65	9	50	9	15	5	-8	21	21	18	49	107	139	44	7	82	82	54	1,154	620	2,598	1,140	366	36
Cash And Cash Equivalents Changes	0	0	33,832	10,132	20,271	-6,772	-19,411	-77,048	58,883	-7,920	-10,949	93,670	16,183	5,912	-3,485	4,085	-9,547	-12,401	782	-1,882	0	16,988	22,428	3,470	1,043	-5,065	4,027	1,186	-2,623	-1,005	-9,554	13,657	-2,878	-5,033	-3,886	-6,744	18,367	-3,950	-3,221	3,336	673	7,647	-1,099	-1,411	1,021	3,763	-1,750	-2,033	-1,403	-3,101	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	71,739	-306	-432	-488	-287	-150	-65	-71	-64	-131	16,589	471	120	183	180	163	139	145	0	192	28	-4	-5	-4	-103	-2	-1	-2	187	1	2	2	-134	6	5	5	1,136	11	0	0	-1,272	0	0	0	-544	-250	-168	206	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	148,228	-6,562	33,832	10,132	20,271	-6,772	-19,411	-77,048	58,883	-7,920	-10,949	93,670	16,183	5,912	-3,485	4,085	-9,546	-12,401	782	-1,882	-10,503	16,988	22,580	3,470	1,043	-5,065	4,027	1,186	-2,623	-1,005	-9,554	13,657	-2,878	-5,033	-3,886	-6,744	18,367	-3,950	-3,221	3,336	673	7,647	-1,099	-1,411	1,021	3,763	-1,750	-2,033	-1,403	-3,101	-384	5,919	-2,749	-5,388	11,543	-1,158	-834	-936	-1,120	-1,830	-1,133	-4,627	-2,566	8,392	-6,671	13,784	0	0	0	0	0	0	0	0
Change In Working Capital	-12,273	-6,297	76,034	1,418	4,860	1,588	-4,447	-5,024	-2,186	5,574	-486	-4,641	18,316	1,370	5,923	-5,473	-3,073	-1,230	-8,178	-55	-9,082	265	2,555	-653	-90	-887	769	-252	43	-242	1,174	-156	1,275	-220	1,263	193	24,671	-25,118	485	-335	794	-555	-109	233	273	295	-278	-134	-706	-1,597	-5	40	1,250	-74	212	258	-2,485	-2,000	-2,249	-2,230	-1,592	-4,381	536	13,864	-585	-360	5,327	-12,614	0	0	0	0	20,411	0
Change Receivables	0	0	-979	4,932	6,280	368	-6,373	-2,937	-5,981	1,321	-3,626	-2,317	2,352	-1,978	6,792	-2,320	-4,623	0	-8,635	-2,046	0	-529	182	-249	-55	129	350	-87	-52	8	-168	-236	384	136	264	230	24,705	-25,323	-913	319	1,154	-457	486	-432	163	147	-128	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-269	10,748	-979	4,932	6,280	368	-6,373	-2,937	-5,981	1,321	-3,626	-2,317	2,352	-1,978	6,792	-2,320	-4,623	0	-8,635	-2,046	529	-529	182	-249	-55	129	350	-87	-52	8	-168	-236	384	136	264	230	24,705	-25,323	-913	319	1,154	-457	486	-432	163	147	84	-250	-168	206	70	-48	514	-251	-360	-231	201	100	124	0	0	-55	-105	0	0	0	0	0	207	0	0	0	0	25
Change To Inventory	671	-315	-724	-1,185	-845	-277	82	280	580	810	205	-248	-1,697	132	-414	-1,221	421	-888	-785	-607	-279	-607	873	0	0	0	3	0	0	0	588	0	0	0	696	0	0	0	1,562	0	0	0	-769	0	0	0	-961	0	0	0	110	0	0	0	-308	0	0	0	2,047	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	5,947	-2,267	-483	1,771	2,017	-2,107	3,249	3,676	2,971	-1,798	1,283	2,931	-398	-1,944	1,115	-345	1,233	2,593	0	756	2,554	-400	-30	-1,012	522	-163	96	-248	1,155	79	889	-358	1,133	-43	-39	200	262	-665	-360	-98	677	665	110	148	394	116	-538	-1,803	82	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	170	0	738	271
Change To Netincome	0	0	3,828	3,050	26,009	3,199	4,140	5,036	4,086	2,471	-885	988	2,168	2,719	1,059	1,483	1,181	1,299	1,790	5,160	5,160	20,283	24,927	2,768	606	681	682	644	396	734	614	661	483	405	621	614	417	309	446	437	233	217	399	312	263	343	390	379	14,867	422	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	0	0	113	-34	25	-35	-34	80	-36	-38	117	-15	-27	-3	-1	3	9	35	35	38	-766	-4	-5	-4	542	-2	0	0	1,228	0	0	0	935	0	0	0	766	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	112	115	132	105	335	711	704	696	698	701	685	687	669	662	670	648	650	646	649	659	668	658	656	43	228	221	214	206	206	189	251	216	220	221	224	212	215	231	232	231	223	231	248	249	249	248	-14,559	236	15,693	857	855	844	835	821	800	823	849	854	824	795	850	969	-2,849	1,027	1,108	1,111	0	0	0	0	0	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	281,263	133,035	139,747	105,915	95,783	75,512	82,284	101,695	178,743	119,860	127,780	138,729	45,059	28,876	22,964	26,449	22,364	31,910	44,311	43,529	45,261	55,914	38,926	16,346	12,876	11,833	16,898	12,871	11,685	14,308	15,313	24,867	11,210	14,088	19,121	23,007	29,751	11,384	15,334	18,555	15,219	14,546	6,899	7,998	9,409	8,388	4,625	6,375	8,408	9,811	12,912	13,296	7,377	10,126	15,514	3,971	5,129	5,963	6,899	8,019	9,849	10,982	15,609	18,175	9,783	16,454	2,670	0	0	0	0	0	0	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	6	-1	-2	-8	-8	-4	-5	-3	5	-7	-5	-5	-1	-5	1	1	0	-9	-1	2	-3	2	-2	-3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-23,992	-16,924	56,627	-17,319	-13,173	-14,334	-19,341	-20,307	-16,668	-7,918	-10,568	-15,099	5,703	1,008	-5,147	-16,361	-11,492	-14,772	-17,132	-13,516	-10,843	-11,875	-6,126	-4,819	-5,038	-6,032	-4,578	-4,559	-5,014	-6,486	-4,393	-4,333	-3,199	-4,504	-3,096	-3,997	21,229	-4,000	-2,958	-1,906	-2,270	-3,785	-3,399	-1,975	-1,814	-1,625	-1,844	-2,162	-2,519	-2,881	1,180	-1,622	-633	-2,228	13,593	-1,461	-1,323	-925	-1,161	-1,871	-1,006	-4,593	-2,579	8,427	-6,917	-4,346	0	0	0	0	0	0	0	0
Investments	-47,148	-1,720	13,863	32,570	33,502	7,470	206	-56,293	-32,965	-131	-25	-32,965	-192	-128	-26	-16	-6	0	-25	-182	0	0	0	0	0	0	2,500	3,351	2,393	5,447	-5,275	1,464	-3	-535	-795	-2,740	-3,036	-1	-250	-2,214	1,400	1,450	2,300	573	2,902	651	97	127	1,118	-331	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	216,200	0	0	0	0	0	0	0	108,476	54	329	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	-36,645	-5,180	-34	-26	-221	-406	-44	-44	-40	-18	-16,663	-15	2,041	-7	-7	-7	14,553	11,390	15,000	15,000	4,558	14,095	15,000	15,000	20,000	0	0	0	20,000	0	0	0	20,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-14,099	-12,612	-22,920	-21,164	-43,452	-18,420	-19,406	-20,976	-19,432	-16,695	-10,010	-12,280	-15,469	-3,801	-12,950	-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-5,782	-5,983	-6,116	-5,140	-67	-7,162	-6,387	-5,041	-5,186	-4,933	-5,146	-4,998	-4,075	20,566	-3,967	-2,187	-3,514	-3,687	-3,947	-2,794	-2,608	-2,551	-2,262	-2,686	-17,460	-2,427	-140	-2,685	-2,695	-3,108	13,073	-2,705	-24	-1,591	-534	-636	-870	-471	-63,579	-5,501	-5,795	-795	0	0	0	0	0	0	0	0
Other Cashflows From Financing Activities	-1,350	935	-1,345	5,131	11,047	10,603	10,233	38,804	84	96	-12	55	-828	107	1,970	168	20,073	-41	-429	31,634	-195	28,863	5,061	14,095	-905	-64	2,374	2,395	2,388	9	132	16,530	329	9	-235	-2,783	179	56	78	452	457	1,442	2,281	560	2,870	647	-114	108	959	114	986	10,081	-2,162	-3,175	-318	318	0	-21	-21	-18	-49	-107	-2	-44	259	-2,494	0	0	0	0	0	0	311	0
Other Cashflows From Investing Activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,708	-15,072	0	0	0	0	0	33	0	0	0	0	0	0	0	0	2	4	-78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,856	0	0	0	0	0	0	0
Other Non Cash Items	-522	-3,724	-51	-244	22,308	-214	-114	1,669	166	162	153	147	211	516	501	494	490	482	424	252	1,311	154	25,254	2,325	606	681	-1	-1	-5,587	-5	1	18	34	34	32	25	23	18	19	2	7	17	29	38	41	44	34,655	19,887	-17,588	43	165	-424	-458	-338	-871	-331	-83	1,519	550	218	655	-603	62,992	-904	-1,622	-4,012	0	0	0	0	0	0	0	0
Sale Purchase Of Stock	0	0	5	-169	-24	154	-21	241	-108,260	47	-329	108,915	25,116	4,919	-295	20,472	1,978	2,412	18,387	536	536	28,863	25,708	9,266	6,081	963	6,099	2,395	0	9	122	16,530	329	9	0	0	179	56	78	452	418	39	4,669	4,669	-66	4,735	0	0	0	114	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	3,590	3,629	1,788	3,050	3,361	3,199	4,140	3,477	2,808	2,471	1,180	988	1,263	2,389	735	1,160	857	977	1,496	1,238	0	1,397	974	443	606	681	682	644	396	734	614	661	483	405	621	614	417	309	448	441	305	217	399	312	263	343	390	379	165	477	579	574	448	451	393	389	420	293	300	0	0	94	756	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	218,485	10,362	-36,658	-5,119	-58	92	-276	-448	108,516	-2	-381	108,769	10,480	4,904	1,662	20,446	1,945	2,371	17,914	11,634	341	28,863	30,266	23,361	6,081	963	6,099	2,395	9	9	122	16,530	329	9	235	235	179	56	-14	7,457	1,620	9,981	-8	4,669	-66	4,735	114	114	114	114	-21	10,081	0	0	484	318	484	0	0	0	0	-2	-2	18,128	259	18,128	10,141	3,339	21,648	18,400	2,772	2,840	25,689	573
Total Cash From Operating Activities	-23,109	-15,204	57,023	-16,835	-12,588	-13,136	-19,123	-20,158	-16,668	-7,787	-10,543	-15,099	5,895	1,136	-5,121	-16,345	-11,486	-14,772	-17,107	-13,334	-10,820	-11,766	-6,081	-4,820	-5,038	-5,968	-4,452	-4,543	-5,009	-6,486	-4,347	-4,302	-3,174	-4,493	-3,006	-3,954	21,251	-3,994	-2,785	-1,852	-2,257	-3,777	-3,380	-1,962	-1,782	-1,621	-1,838	-2,143	-2,360	-2,660	1,245	-1,613	-583	-2,219	13,608	-1,461	-1,323	-925	-1,140	-1,853	-957	-4,486	-2,440	8,471	-6,910	-4,264	0	0	0	0	0	0	0	0
Total Cashflows From Investing Activities	0	0	13,467	32,086	32,917	6,272	-12	-56,442	-32,965	-131	-25	-25	-192	-128	-26	-16	-6	-6	-25	-182	-182	-109	-1,753	-15,071	-15,071	-64	2,374	3,335	2,388	5,480	-5,321	1,433	-28	-546	-885	-2,783	-3,058	-7	-421	-2,264	1,309	1,442	2,281	560	2,870	647	91	108	959	-552	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,775	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31
Cost Of Revenue	4,632	8,326	8,177	5,824	2,687	18,502	16,178	14,880	14,381	78	16,124	13,180	11,680	11,613	10,636	13,360	24,094	24,325	20,436	0	0	0	-
Depreciation And Amortization	464	4,181	2,752	2,518	3,514	1,148	815	908	882	917	994	2,227	3,355	3,326	3,438	397	8,718	8,699	1,242	1,242	241	212	516
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	-73,662	-78,938	-55,276	-37,290	-47,861	-27,321	-18,576	-21,774	6,421	-13,562	-13,009	2,053	-14,485	6,107	-4,474	26,492	54,177	-30,745	-9,021	-9,021	-7,252	-3,597	-1,795
Ebitda	-73,198	-74,757	-52,524	-34,772	-44,347	-26,173	-17,761	-20,866	7,303	-12,645	-12,015	4,280	-11,130	9,433	-1,036	26,889	62,895	-22,046	-7,779	-7,779	-7,011	-3,385	-1,279
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	41,386	33,078	28,762	28,613	17,678	2,961	7,539	1,620	26,565	3,395	2,143	3,526	4,965	23,053	12,162	3,476	2,235	1,465	630	630	265	74	516
Income Before Tax	-70,712	-102,254	-58,417	-45,394	-56,793	-53,171	-18,485	-21,702	6,443	-13,485	-12,017	-25,004	-8,846	8,776	-3,462	-76,153	-127,203	-27,982	-11,486	-11,486	-5,225	-3,598	-2,252
Income Tax Expense	83	22,258	5,498	7,257	6,176	-25,558	-815	-155	96	-130	-117	-169	-218	23	-951	-483	-23,529	-7,068	-303	-303	-2,665	-1,741	-1,795
Interest Expense	1,247	3,189	5,498	7,257	6,176	720	0	0	0	1	2	0	0	0	0	507	1,941	3,374	3,374	0	4	0	0
Interest Income	6,949	2,131	292	58	1,054	20,161	101	91	72	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	-70,795	-124,512	-63,915	-52,651	-62,969	-53,171	-18,485	-21,547	6,347	-13,355	-11,900	-24,835	-8,628	8,753	-2,511	-75,670	-103,675	-20,913	-11,183	-11,183	-2,559	-1,858	-2,252
Net Income Applicable To Common Shares	0	-102,254	-58,417	-45,394	-56,793	-86,126	-53,171	-18,485	-21,547	6,347	-13,355	-11,900	-24,835	0	8,753	0	0	0	0	0	0	0	-
Net Income From Continuing Ops	-70,795	-102,254	-58,417	-45,394	-56,793	-86,126	-53,171	-18,485	-21,547	6,347	-13,355	-11,900	-24,835	0	0	0	0	0	0	0	0	0	-
Net Interest Income	5,702	-1,058	-5,206	-7,199	-5,122	0	-619	91	72	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Operating Income Net Other	0	572	2,357	-847	-2,756	0	-26,177	91	75	18	5	21	207	0	0	0	0	0	0	0	0	0	-
Non Recurring	0	20,699	0	0	0	0	0	0	0	0	-78	0	14,830	0	0	0	0	0	0	0	0	0	-
Operating Income	-73,662	-78,938	-55,276	-37,290	-47,861	-26,274	-18,576	-21,774	6,421	-13,490	-12,031	-25,211	-10,003	9,091	-4,636	-24,901	-35,542	-27,676	-10,254	-10,254	-6,237	-3,598	-1,795
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	119,680	120,342	92,215	71,727	68,226	29,235	26,115	23,394	20,144	17,041	14,174	13,907	14,968	13,962	16,798	28,377	37,777	29,142	10,883	10,883	6,502	3,672	1,795
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Reconciled Depreciation	464	2,446	2,771	2,649	2,604	0	1,148	815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Research Development	64,362	49,642	28,500	17,424	15,368	16,178	14,880	14,381	12,088	9,573	7,005	7,039	6,864	6,994	8,007	14,426	20,030	11,702	6,294	6,294	4,872	3,081	1,795
Selling And Marketing Expenses	11,689	25,507	27,503	25,293	29,772	1,512	1,512	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Selling General Administrative	40,102	34,817	25,575	20,726	17,939	11,545	11,235	9,013	8,056	7,468	7,169	6,868	8,104	6,968	8,791	13,951	13,951	0	0	10,127	6,477	3,643	-
Tax Provision	83	0	0	0	0	0	0	0	-155	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Operating Expenses	115,048	112,016	84,038	65,903	65,539	29,235	26,115	23,394	20,144	17,041	14,174	13,907	14,968	13,962	16,798	28,377	37,777	29,142	10,883	10,883	6,502	3,672	1,795
Total Other Income Expense Net	2,950	-23,316	-3,141	-8,104	-8,932	-26,278	91	72	3	78	-2	-14,661	1,127	-342	1,012	-51,393	-89,719	3,069	-1,233	-1,233	1,016	-1	-2,252
Total Revenue	46,018	41,404	36,939	34,437	20,365	2,961	7,539	1,620	26,565	3,473	2,143	3,526	4,965	23,053	12,162	3,476	2,235	1,465	630	630	265	74	516

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30
Cost Of Revenue	998	1,202	1,792	640	3,410	1,405	1,734	1,777	3,033	1,825	1,929	1,390	2,461	1,882	502	980	1,324	327	706	330	4,179	6,233	4,765	3,325	6,513	6,170	6,623	5,544	5,823	6,838	6,291	5,204	5,544	5,229	5,385	5,168	4,422	4,287	78	4	3,982	4,084	4,225	3,076	2,984	2,895	2,738	3,029	2,580	3,333	3,168	2,655	2,700	3,090	2,748	2,555	2,697	2,636	2,228	3,149	3,541	2,228	5	3,471	7,056	3,471	7,906	7,217	9,008	8,924	13,064	-7,372	7,372	-	0	0	0	-	0	-	-	-	0	-	-	-
Depreciation And Amortization	112	1,786	1,623	1,202	1,269	1,255	977	757	615	615	685	687	615	615	670	615	615	646	649	615	238	658	656	43	228	221	214	206	206	189	251	216	220	221	224	212	215	231	232	231	223	231	248	249	249	248	-14,559	236	15,693	857	855	844	835	821	800	823	849	854	824	795	850	969	-2,849	1,027	1,108	1,111	0	-	38,058	-	-39,275,543	-	0	-	-1,029,382	-	0	-	0	-	-	-	0	-	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Ebit	-16,354	-14,398	-22,761	-21,554	-23,036	-18,398	-19,216	-18,284	-18,044	-15,307	-10,699	-10,935	-12,737	-1,957	-11,144	-11,390	-8,623	-13,877	-9,899	-14,408	-11,005	-14,083	-10,411	-2,353	-6,036	-6,006	-6,350	-5,366	-300	-7,375	-6,707	-5,096	-5,458	-4,984	-5,424	-5,052	-4,331	20,789	-4,011	-2,222	-3,835	-3,948	-4,227	-2,812	-2,893	-2,837	12,249	-2,728	-3,804	-3,428	-1,171	-3,473	-3,576	-3,765	11,000	-3,916	-1,041	549	-48	-759	-1,643	-3,724	56,700	-7,787	-10,225	-9,347	0	0	-8,908	0	39,246,811	0	0	-	1,018,647	0	0	-	0	-	-	-	0	-	-	-
Ebitda	-16,242	-12,612	-21,138	-20,352	-21,767	-17,143	-18,239	-17,527	-17,429	-14,692	-10,014	-10,248	-12,122	-1,342	-10,474	-10,775	-8,008	-13,231	-9,250	-13,793	-10,767	-13,425	-9,755	-2,310	-5,808	-5,785	-6,136	-5,160	-94	-7,186	-6,456	-4,880	-5,238	-4,763	-5,200	-4,840	-4,116	21,020	-3,779	-1,991	-3,612	-3,717	-3,979	-2,563	-2,644	-2,589	-2,310	-2,492	11,889	-2,571	-316	-2,629	-2,741	-2,944	11,800	-3,093	-192	1,403	776	36	-793	-2,755	53,851	-6,760	-9,117	-8,236	-37,322	65	29,150	790	-28,732	352	671	375	-10,735	160	162	151	-6,455	73	72	65	-3,648	17	16	15
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Gross Profit	13,030	14,000	7,313	7,043	7,123	8,607	9,831	7,517	8,511	7,234	7,084	5,933	4,670	13,813	3,620	6,509	7,309	2,182	6,504	1,682	2,442	486	715	928	933	385	701	590	5,971	277	304	324	526	466	409	328	521	25,307	214	1,988	592	597	492	513	585	553	699	538	630	1,659	3,715	360	414	476	15,722	515	3,433	3,383	995	3,163	2,970	578	2,698	542	128	-3,368	455	65	837	790	410	352	671	375	148	160	162	151	47	73	72	65	24	17	16	15
Income Before Tax	-14,016	-12,612	-22,920	-21,164	-43,452	-18,420	-19,406	-20,976	-19,432	-16,695	-10,010	-12,280	-15,469	-3,801	-12,950	-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-5,782	-5,983	-6,116	-5,140	-67	-7,162	-6,425	-5,075	-5,228	-4,974	-5,194	-5,042	-4,113	20,792	-4,010	-2,218	-3,540	-3,717	-3,979	-2,809	-2,645	-2,584	-2,302	-2,716	-17,504	-2,482	-289	-2,798	-2,660	-3,099	13,058	-2,633	-34	-1,615	-621	-741	-1,144	-956	-63,823	-5,516	-5,811	-1,003	-13,439	-8,706	-50,208	37,562	-4,044	-5,623	-5,765	-5,994	-2,637	-2,849	-2,875	-2,678	-450	-703	-693	-626	-604	-418	-388	-375
Income Tax Expense	83	0	-1,188	422	20,699	22	190	1,559	1,388	6	1,376	0	1,827	0	8	54	362	183	266	1,020	0	157	64	2,300	-228	0	-214	-206	-206	-189	-38	-34	-42	-41	-48	-44	-38	226	-43	-31	-26	-30	-32	-15	-37	-33	-40	-30	-44	-55	-149	-113	35	9	-15	72	-10	-24	-87	-105	-274	-485	-244	-15	-16	-208	13,439	8,706	-10,425	-37,562	4,044	5,623	5,765	5,994	2,637	2,849	2,875	2,678	450	703	693	626	604	418	388	375
Interest Expense	0	0	435	812	781	662	552	1,194	1,388	1,388	1,376	1,345	1,827	1,844	1,806	1,784	1,787	1,770	1,599	1,020	827	815	720	720	720	0	720	0	0	0	720	0	0	0	720	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	150	150	151	150	349	1,962	3,242	3,788	3,162	211	211	-	0	0	0	-	4	-	-	-	0	-	-	-
Interest Income	2,338	1,786	1,623	1,202	1,064	640	362	61	6	6	280	0	0	0	8	54	362	183	266	777	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	8	0	0	-	0	-	-	-	0	-	-	-
Net Income	-14,099	-12,612	-22,920	-21,586	-64,151	-18,442	-19,596	-22,535	-19,432	-16,695	-10,010	-12,280	-15,469	-3,801	-12,950	-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-5,782	-5,983	-6,116	-5,140	-67	-7,162	-6,387	-5,041	-5,186	-4,933	-5,146	-4,998	-4,075	20,566	-3,967	-2,187	-3,514	-3,687	-3,947	-2,794	-2,608	-2,551	-2,262	-2,686	-17,460	-2,427	-140	-2,685	-2,695	-3,108	13,073	-2,705	-24	-1,591	-534	-636	-870	-471	-63,579	-5,501	-5,795	-795	-13,439	-8,706	-39,783	37,562	-4,044	-5,623	-5,765	-5,994	-2,637	-2,849	-2,875	-2,678	-450	-703	-693	-626	-604	-418	-388	-375
Net Income Applicable To Common Shares	0	0	-22,920	-21,164	-43,452	-18,420	-19,406	-20,976	-19,432	-16,695	-10,010	-12,280	-15,469	-3,801	-12,950	-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-5,782	-5,983	-6,116	-5,140	-67	-7,162	-6,387	-5,041	-5,186	-4,933	-5,146	-4,998	-4,075	20,566	-3,967	-2,187	-3,514	-3,687	-3,947	-2,794	-2,608	-2,551	-2,262	-2,686	-17,460	-2,427	0	0	0	0	13,073	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Net Income From Continuing Ops	-14,099	-12,612	-22,920	-21,164	-43,452	-18,420	-19,406	-20,976	-19,432	-16,695	-10,010	-12,280	-15,469	-3,801	-12,950	-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-5,782	-5,983	-6,116	-5,140	-67	-7,162	-6,387	-5,041	-5,186	-4,933	-5,146	-4,998	-4,075	20,566	-3,967	-2,187	-3,514	-3,687	-3,881	-2,794	-2,608	-2,617	-2,262	-2,686	-17,460	-2,427	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Net Interest Income	2,338	1,786	1,188	390	283	-22	-190	-1,133	-1,382	-1,382	-1,096	-1,345	-1,827	-1,844	-1,798	-1,730	-1,425	-1,587	-1,333	-777	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Non Operating Income Net Other	0	0	276	1,202	1,068	640	362	-1,498	5	6	2,345	1	-905	-4	8	54	362	183	266	-3,567	0	-18,757	-23,926	-2,300	26	23	18	21	27	25	29	30	4	12	6	11	1	0	3	0	1	1	6	3	-2	14	8	11	139	49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Non Recurring	0	0	0	0	20,699	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2	-4	-72	0	0	0	0	0	0	0	14,830	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Operating Income	-16,354	-14,398	-22,761	-21,554	-23,036	-18,398	-19,216	-18,284	-18,050	-15,313	-10,979	-10,935	-12,737	-1,957	-11,152	-11,444	-8,986	-14,060	-10,165	-14,651	-11,005	-13,554	-9,782	-4,678	-5,808	-6,006	-6,136	-5,160	-94	-7,186	-6,456	-5,096	-5,238	-4,984	-5,200	-5,052	-4,116	20,789	-4,012	-2,219	-3,541	-3,718	-3,981	-2,812	-2,648	-2,590	-2,310	-2,727	-17,643	-2,531	-308	-3,139	-3,121	-3,435	12,174	-2,863	-113	-107	-55	-781	-1,421	-2,379	-5,043	-6,609	-8,036	-5,213	-37,322	65	-8,908	790	39,246,811	352	671	375	8,287,457	160	162	151	-6,455	73	72	65	-3,648	17	16	15
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	-	-	-	0	-	-	-
Other Operating Expenses	30,382	29,600	31,866	29,237	33,569	28,410	30,781	27,578	29,594	24,372	19,992	18,258	19,868	17,652	15,274	18,933	17,619	16,569	17,375	16,663	13,447	14,040	10,497	5,606	6,741	6,391	6,837	5,750	6,065	7,463	6,760	5,420	5,764	5,450	5,609	5,380	4,637	4,518	4,306	4,215	4,205	4,315	4,473	3,325	3,233	3,143	3,009	3,265	3,443	4,190	4,023	3,499	3,535	3,911	3,548	3,378	3,546	3,490	3,278	3,944	4,391	5,185	7,746	7,151	8,164	5,316	37,777	0	9,745	0	39,248,209	0	0	-	8,287,930	0	0	-	6,502	-	-	-	3,672	-	-	-
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Reconciled Depreciation	112	115	132	105	335	615	615	696	698	701	685	687	669	662	670	648	650	646	649	659	668	658	656	43	228	221	214	206	206	189	251	216	220	221	224	212	215	231	232	231	223	231	248	249	249	248	-14,559	236	15,693	857	855	844	835	821	800	823	849	854	824	795	850	969	-2,849	1,111	1,108	1,111	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Research Development	17,951	17,363	15,730	13,618	15,543	11,162	12,992	9,945	8,918	8,498	5,605	5,479	5,205	4,090	3,276	4,853	4,132	3,484	3,955	3,797	4,179	6,233	4,765	3,325	4,269	3,819	4,213	3,324	3,165	4,178	4,104	3,074	3,721	3,482	3,198	3,339	2,767	2,784	2,306	2,269	2,494	2,504	2,320	1,587	1,575	1,523	1,410	1,508	1,992	2,129	1,851	1,737	1,534	1,742	1,786	1,680	1,728	1,800	1,830	1,892	2,057	2,765	2,404	3,605	4,946	89	83,370	5,153	5,721	6,267	17,855,265	0	0	-	8,287,930	0	0	-	4,875	-	-	-	3,079	-	-	-
Selling And Marketing Expenses	185	479	5,288	5,737	5,915	6,016	6,883	6,693	7,811	7,374	6,659	5,659	5,810	5,269	6,089	8,125	7,399	7,778	7,284	7,311	4,528	3,646	1,512	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8,609	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Selling General Administrative	11,248	10,556	9,056	9,242	8,496	9,212	8,557	8,548	9,217	6,060	5,184	5,115	5,777	5,796	4,792	4,360	4,149	4,365	4,815	4,610	4,740	4,161	4,220	2,281	2,472	2,572	2,624	2,426	2,900	3,285	2,656	2,346	2,043	1,968	2,411	2,041	1,870	1,734	2,000	1,946	1,711	1,811	2,153	1,738	1,658	1,620	1,599	1,757	1,451	2,061	2,172	1,762	2,001	2,169	1,762	1,698	1,818	1,690	1,448	2,052	2,334	2,957	13,951	3,546	3,218	0	0	0	0	0	0	0	0	-	4,984	5,927	5,927	-	6,477	-	-	-	3,643	-	-	-
Tax Provision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	0	-	-	-
Total Operating Expenses	29,384	28,398	30,074	28,597	30,159	27,005	29,047	25,801	26,561	22,547	18,063	16,868	17,407	15,770	14,772	17,953	16,295	16,242	16,669	16,333	13,447	14,040	10,497	5,606	6,741	6,391	6,837	5,750	6,065	7,463	6,760	5,420	5,764	5,450	5,609	5,380	4,637	4,518	4,306	4,215	4,205	4,315	4,473	3,325	3,233	3,143	3,009	3,265	3,443	4,190	4,023	3,499	3,535	3,911	3,548	3,378	3,546	3,490	3,278	3,944	4,391	2,957	7,746	7,151	8,164	1,845	-37,777	0	9,745	0	-39,248,209	0	0	-	-8,287,930	0	0	-	-6,502	-	-	-	-3,672	-	-	-
Total Other Income Expense Net	2,338	1,786	-1,347	390	-20,416	-22	-190	-2,692	-1,388	-1,382	2,065	-1,345	-905	-1,844	-1,798	-1,730	-1,425	-1,587	-1,333	-3,810	-589	-18,886	-23,953	-2,325	26	23	20	20	27	24	31	21	10	10	-1	4	3	3	2	4	72	1	2	3	3	-1	8	1	-14,702	40	8	334	455	330	859	230	79	-1,510	-573	18	222	1,345	-58,894	1,178	2,189	4,134	23,883	-8,771	-38,058	36,771	-76,915,363	-5,975	-6,435	-6,369	-23,404,775	-3,009	-3,036	-2,829	6,005	-776	-765	-691	3,044	-435	-403	-390
Total Revenue	14,028	15,202	9,105	7,683	10,533	10,012	11,565	9,294	11,544	9,059	9,013	7,323	7,131	15,695	4,122	7,489	8,633	2,509	7,210	2,012	2,442	486	715	928	933	385	701	590	5,971	277	304	324	526	466	409	328	521	25,307	292	1,992	592	597	492	513	585	553	699	538	630	1,659	3,715	360	414	476	15,722	515	3,433	3,383	3,223	3,163	2,970	2,806	2,703	542	128	103	455	65	837	790	410	352	671	375	148	160	162	151	47	73	72	65	24	17	16	15

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	46,018
Cost of Revenue	-4,632
Gross Profit	41,386	41,386

Operating Income (+$)
Gross Profit	41,386
Operating Expense	-115,048
Operating Income	-73,662	-73,662

Operating Expense (+$)
Research Development	64,362
Selling General Administrative	40,102
Selling And Marketing Expenses	11,689
Operating Expense	115,048	116,153

Net Interest Income (+$)
Interest Income	6,949
Interest Expense	-1,247
Other Finance Cost	-0
Net Interest Income	5,702

Pretax Income (+$)
Operating Income	-73,662
Net Interest Income	5,702
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-70,712	-76,612 EBIT - interestExpense = -74,909 -70,712 -69,548
Interest Expense	1,247
Earnings Before Interest and Taxes (EBIT)	-73,662	-69,465
Earnings Before Interest and Taxes (EBITDA)	-73,198

After tax Income (+$)
Income Before Tax	-70,712
Tax Provision	-83
Net Income From Continuing Ops	-70,795	-70,795
Net Income	-70,795
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	119,680
Total Other Income/Expenses Net	2,950	-5,702

Technical Analysis of Eyepoint Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eyepoint Pharmaceuticals Inc. The general trend of Eyepoint Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eyepoint Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (0.0%)		Bearish trend (0.0%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Eyepoint Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 19.03 < 19.40 < 23.97.

The bearish price targets are: 15.63 > 12.25 > 9.1.

Tweet this

Eyepoint Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eyepoint Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Eyepoint Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eyepoint Pharmaceuticals Inc. The current macd is -0.83827225.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eyepoint Pharmaceuticals Inc price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eyepoint Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eyepoint Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Eyepoint Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Eyepoint Pharmaceuticals Inc. The current adx is 19.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Eyepoint Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1

Eyepoint Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eyepoint Pharmaceuticals Inc. The current sar is 23.65.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Eyepoint Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eyepoint Pharmaceuticals Inc. The current rsi is 30.10. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Eyepoint Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eyepoint Pharmaceuticals Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH < 20: The STOCH %K is below 20 and oversold. -2
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eyepoint Pharmaceuticals Inc price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Eyepoint Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eyepoint Pharmaceuticals Inc. The current cci is -219.22662115.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1

Eyepoint Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eyepoint Pharmaceuticals Inc. The current cmo is -48.5787572.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Eyepoint Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Eyepoint Pharmaceuticals Inc. The current willr is -92.75471698.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1

Eyepoint Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Eyepoint Pharmaceuticals Inc.

Eyepoint Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eyepoint Pharmaceuticals Inc. The current atr is 1.54718322.

Eyepoint Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eyepoint Pharmaceuticals Inc. The current obv is 37,990,464.

Eyepoint Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eyepoint Pharmaceuticals Inc. The current mfi is 40.07.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Eyepoint Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Eyepoint Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-11-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-01	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-04	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-05	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-06	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-07	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-18	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-26	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-27	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-04	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-05	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-17	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-22	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-26	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-01-30	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-31	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-01	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-02-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-05	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-02-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-07	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-02-08	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-02-09	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-02-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-13	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-02-14	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-20	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-21	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-23	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-27	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-29	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-04	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-08	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-11	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-18	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-19	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-20	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-21	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-25	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-26	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-28	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-02	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-04-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-08	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-09	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-11	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-04-12	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-15	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-16	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-17	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-18	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).

6.3. Candlestick Patterns

Eyepoint Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Eyepoint Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	30.099
Ma 20	Greater than	Ma 50	21.104
Ma 50	Greater than	Ma 100	24.096
Ma 100	Greater than	Ma 200	22.315
Open	Greater than	Close	20.790
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about Eyepoint Pharmaceuticals Inc

I send you an email if I find something interesting about Eyepoint Pharmaceuticals Inc.

Eyepoint Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Eyepoint Pharmaceuticals Inc together

Get notifications about Eyepoint Pharmaceuticals Inc

Quick analysis of Eyepoint Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Eyepoint Pharmaceuticals Inc (5 min.)

$17.50

$5.34

$-33.74 - $-11.96

$-28.40 - $-6.62

2. Growth of Eyepoint Pharmaceuticals Inc (5 min.)

Is Eyepoint Pharmaceuticals Inc growing?

How much money is Eyepoint Pharmaceuticals Inc making?

How much money comes from the company's main activities?

3. Financial Health of Eyepoint Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc? (5 min.)

What can you expect buying and holding a share of Eyepoint Pharmaceuticals Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Eyepoint Pharmaceuticals Inc

About Eyepoint Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Eyepoint Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Eyepoint Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Eyepoint Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Eyepoint Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Eyepoint Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Eyepoint Pharmaceuticals Inc
Buy, Hold or Sell?